

# openheart Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF

Jelle C L Himmelreich <sup>1,2,3</sup>, Saverio Viridone,<sup>2</sup> John Camm,<sup>4</sup> Karen Pieper,<sup>2</sup> Ralf E Harskamp,<sup>1,3</sup> Ali Oto,<sup>5</sup> Barry F Jacobson,<sup>6</sup> J P S Sawhney,<sup>7</sup> Toon Wei Lim,<sup>8</sup> Harry Gibbs,<sup>9</sup> Shinya Goto,<sup>10</sup> Sylvia Haas,<sup>11</sup> Keith A A Fox,<sup>12</sup> Petr Jansky,<sup>13</sup> Freek Verheugt,<sup>14</sup> Ajay K Kakkar,<sup>2,15</sup> GARFIELD-AF investigators

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/openhrt-2024-002708>).

**To cite:** Himmelreich JCL, Viridone S, Camm J, *et al.* Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF. *Open Heart* 2024;**11**:e002708. doi:10.1136/openhrt-2024-002708

Received 9 April 2024  
Accepted 19 June 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

**Correspondence to**  
Dr Jelle C L Himmelreich; j.c.himmelreich@amsterdamumc.nl

## ABSTRACT

**Background** The extent to which differences in results from Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial (ROCKET) atrial fibrillation (AF)—the landmark trials for the approval of apixaban and rivaroxaban, respectively, for non-valvular AF—were influenced by differences in their protocols is debated. The potential influence of selection criteria on trial results was assessed by emulating these trials in data from the Global Anticoagulant Registry in the Field (GARFIELD)-AF registry.

**Methods** Vitamin K antagonist (VKA) and non-vitamin K oral antagonist (NOAC) users from GARFIELD-AF were selected according to eligibility for the original ARISTOTLE or ROCKET AF trials. A propensity score overlap weighted Cox model was used to emulate trial randomisation between treatment groups. Adjusted HRs for stroke or systemic embolism (SE) within 2 years of enrolment were calculated for each NOAC versus VKA.

**Results** Among patients on apixaban, rivaroxaban and VKA, 2570, 3560 and 8005 were eligible for ARISTOTLE, respectively, and 1612, 2005 and 4368, respectively, for ROCKET AF. When selecting for ARISTOTLE criteria, apixaban users had significantly lower stroke/SE risk versus VKA (HR 0.57; 95% CI 0.34 to 0.94) while no reduction was observed with rivaroxaban (HR 0.98; 95% CI 0.68 to 1.40). When selecting for ROCKET AF criteria, safety and efficacy versus VKA were similar across the NOACs.

**Conclusion** Apixaban and rivaroxaban showed similar results versus VKA in high-risk patients selected according to ROCKET AF criteria, whereas differences emerged when selecting for the more inclusive ARISTOTLE criteria. Our results highlight the importance of trial selection criteria in interpreting trial results and underline the problems faced in comparing treatments across rather than within clinical trials.

## INTRODUCTION

Oral anticoagulation (OAC) treatment effectively decreases the burden of stroke and mortality in at-risk atrial fibrillation

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ It has been suggested that differences in trial design contributed to outcomes of the landmark trials for the approval of apixaban (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation, ARISTOTLE) and rivaroxaban (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)) for non-valvular atrial fibrillation. This has hampered comparison of the safety and efficacy of the two non-vitamin K oral anticoagulants based on the trial data.


## WHAT THIS STUDY ADDS

⇒ By emulating the randomised clinical trials in a real-world patient population, this study shows that all three oral anticoagulants achieved similar results in high-risk patients selected according to ROCKET AF criteria. In patients selected according to the more inclusive ARISTOTLE criteria, apixaban but not rivaroxaban showed clinical benefit compared with vitamin K antagonist for reducing the risk of stroke/systemic embolism.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The results highlight the importance of trial selection criteria for interpreting trial results and underline the importance of high-quality observational data for assessment of relative drug performance in real-world populations.

(AF) patients. Non-vitamin K oral anticoagulants (NOACs) are non-inferior to vitamin K antagonists (VKA) in reducing stroke risk while being associated with a lower risk of bleeding.<sup>1</sup> If indicated from the CHA<sub>2</sub>DS<sub>2</sub>-VASc score, current guidelines recommend NOACs rather than VKAs for stroke prophylaxis in non-valvular AF, without making general recommendations regarding specific NOACs.<sup>1-3</sup> The most recent NICE guidance notes an absence of direct clinical



**Figure 1** Study flow chart. ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; GARFIELD-AF, Global Anticoagulant Registry in the FIELD; IC, inclusion criterion; ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; VKA, vitamin K antagonists.

head-to-head comparisons that would allow such a distinction.<sup>3</sup>

Researchers are, therefore, dependent on an indirect approach, comparing safety and efficacy outcomes of published randomised trials of various NOACs versus VKA. This approach, however, is hampered by considerably different study protocols.<sup>4</sup> This applies specifically to the two landmark trials for approval of the factor Xa inhibitors apixaban and rivaroxaban—ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF) and ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in AF).<sup>5 6</sup> In these trials, non-identical patient selection criteria resulted in much higher cardiovascular disease burden among patients in ROCKET AF compared with ARISTOTLE. Moreover, these trials used different definitions for their primary safety endpoint, further impeding a comparison of the relative efficacy and safety of each NOAC versus VKA.

In the current work, we investigate the influence of the trials' inclusion and exclusion criteria on results for safety and efficacy of apixaban and rivaroxaban versus VKA using uniform endpoints in an international AF patient registry.

## METHODS

### Global Anticoagulant Registry in the Field-AF registry

The Global Anticoagulant Registry in the Field (GARFIELD-AF) registry is a prospective, multinational observational study that includes patients with newly

diagnosed non-valvular AF from 1215 representative sites across 35 countries.<sup>7</sup> Adults diagnosed with AF in the past 6 weeks, and at least one risk factor for stroke according to their local practitioner, were eligible for inclusion. Excluded were patients with a transient reversible cause for AF. Patients were enrolled prospectively and consecutively in five separate, sequential cohorts in order to minimise recruitment bias.

Choice of prophylactic treatment was at the discretion of the local practitioner. All participants were followed up for 2 years after enrolment. Inclusion and follow-up in GARFIELD-AF have been completed, and the database has been closed.

### Patient selection

The current analysis involved patients from GARFIELD-AF cohorts 3–5 (n=34 903, recruited from April 2013 to August 2016) who were treated at baseline with either apixaban, rivaroxaban or VKA. GARFIELD-AF cohort 1 (enrolment period: 2010–2011) and cohort 2 (2011–2013) were not included because NOACs had not been introduced in many participating countries at that time. Baseline treatment was defined as a participant's first registered stroke prophylaxis by OAC, regardless of dosage or concomitant antiplatelet (AP) use. Patients were excluded if treatment or follow-up information was missing.

### Baseline data collection

Oversight of operations and data management of the GARFIELD-AF registry were conducted by the Thrombosis Research Institute (TRI; London, UK), with support from Quintiles (Durham, North Carolina, USA),

**Table 1** Baseline characteristics for ARISTOTLE trial eligible patients by OAC treatment at baseline

Baseline characteristics	Treatment at baseline		
	Apixaban (n=2570)	Rivaroxaban (N=3560)	VKA (N=8005)
Female sex, n (%)	1240 (48.2)	1599 (44.9)	3747 (46.8)
Age, median (Q1; Q3), years	76.0 (69.0; 81.0)	73.0 (65.0; 79.0)	71.0 (64.0; 77.0)
Ethnicity, n (%)			
Caucasian	1513 (60.8)	2507 (71.5)	5296 (67.3)
Hispanic/Latino	70 (2.8)	199 (5.7)	666 (8.5)
Asian	859 (34.5)	722 (20.6)	1730 (22.0)
Afro-Caribbean/mixed/other	46 (1.8)	79 (2.3)	174 (2.2)
Body mass index, median (Q1; Q3), kg/m <sup>2</sup>	26.2 (23.4; 29.8)	27.5 (24.4; 31.3)	27.8 (24.6; 32.0)
Systolic blood pressure, median (Q1; Q3), mm Hg	130.0 (120.0; 142.0)	132.0 (120.0; 144.0)	130.0 (120.0; 144.0)
Diastolic blood pressure, median (Q1; Q3), mm Hg	79.0 (70.0; 85.0)	80.0 (70.0; 86.0)	80.0 (70.0; 88.0)
Pulse, median (Q1; Q3), bpm	84.0 (70.0; 107.0)	84.0 (70.0; 105.0)	84.0 (72.0; 100.0)
Type of atrial fibrillation, n (%)			
Permanent	340 (13.2)	472 (13.3)	1398 (17.5)
Persistent	392 (15.3)	587 (16.5)	1358 (17.0)
Paroxysmal	895 (34.8)	1104 (31.0)	1736 (21.7)
New onset (unclassified)	943 (36.7)	1397 (39.2)	3513 (43.9)
Care setting specialty at diagnosis, n (%)			
Internal medicine/neurology/geriatrics	486 (18.9)	679 (19.1)	1558 (19.5)
Cardiology	1826 (71.1)	2439 (68.5)	5122 (64.0)
Primary care/general practice	258 (10.0)	442 (12.4)	1325 (16.6)
Care setting location at diagnosis, n (%)			
Hospital	1190 (46.3)	1653 (46.4)	4643 (58.0)
Office/anticoagulation clinic/thrombosis centre	1142 (44.4)	1582 (44.4)	2514 (31.4)
Emergency room	238 (9.3)	325 (9.1)	848 (10.6)
Medical history, n (%)			
Heart failure	567 (22.1)	820 (23.0)	2046 (25.6)
Acute coronary syndromes	227 (8.9)	336 (9.5)	798 (10.0)
Vascular disease*	491 (19.3)	802 (22.8)	1947 (24.6)
Carotid occlusive disease	90 (3.6)	97 (2.8)	176 (2.2)
VTE	53 (2.1)	108 (3.1)	260 (3.3)
Prior stroke/TIA/SE	366 (14.4)	375 (10.6)	1032 (13.0)
Hypertension	2082 (81.2)	3020 (84.9)	6761 (84.7)
Hypercholesterolaemia	1114 (44.3)	1655 (48.2)	3506 (46.0)
Diabetes	621 (24.2)	917 (25.8)	2219 (27.7)
Moderate to severe CKD	219 (8.8)	288 (8.4)	469 (6.3)
Current smoker, n (%)	181 (7.9)	309 (9.6)	694 (9.4)
AP treatment, n (%)	372 (14.7)	539 (15.4)	1665 (20.8)
CHADS2 score, median (Q1; Q3)	2.0 (1.0; 3.0)	2.0 (1.0; 2.0)	2.0 (1.0; 3.0)
CHADS2 score 0–1, n (%)	707 (29.4)	1124 (33.7)	2345 (31.5)
CHADS2 score 2, n (%)	1005 (41.8)	1398 (41.9)	3198 (43.0)
CHADS2 score ≥3, n (%)	690 (28.7)	815 (24.4)	1896 (25.5)
CHA2DS2-VASc score, median (Q1; Q3)	4.0 (3.0; 4.0)	3.0 (2.0; 4.0)	3.0 (3.0; 4.0)
HAS-BLED score†, median (Q1; Q3)	1.0 (1.0; 2.0)	1.0 (1.0; 2.0)	1.0 (1.0; 2.0)
GARFIELD-AF mortality score‡, median (Q1; Q3)	4.6 (2.9; 7.7)	4.1 (2.4; 6.9)	5.0 (3.0; 7.7)

Continued

Table 1 Continued

Baseline characteristics	Treatment at baseline		
	Apixaban (n=2570)	Rivaroxaban (N=3560)	VKA (N=8005)
GARFIELD-AF stroke score §¶, median (Q1; Q3)	1.4 (1.0; 1.9)	1.2 (0.9; 1.7)	1.5 (1.1; 2.0)
GARFIELD-AF bleeding score§**, median (Q1; Q3)	1.7 (1.2; 2.2)	1.5 (1.1; 2.0)	2.1 (1.5; 2.7)

\*Defined as peripheral artery disease and/or coronary artery disease.

†The risk factor 'labile INRs' is not included in the HAS-BLED score as it is not collected at baseline. As a result, the maximum HAS-BLED score at baseline is 8 points (not 9).

‡Represents the expected probability of dying within 2 years follow-up.

§The GARFIELD-AF risk scores use different coefficients for NOAC and VKA treatment, leading to higher estimated risk in VKA users versus NOAC users with the same baseline characteristics. The scores are not impacted by the type of NOAC.

¶Represents the expected probability of developing a non-haemorrhagic stroke/SE within 2 years follow-up.

\*\*Represents the expected probability of developing a major bleeding within 2 years follow-up.

AP, antiplatelet; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events; CKD, chronic kidney disease; GARFIELD, Global Anticoagulant Registry in the Field; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; NOAC, non-vitamin K oral antagonist; OAC, oral anticoagulation; SE, systemic embolism; TIA, transient ischaemic attack; VKA, vitamin K antagonist; VTE, venous thromboembolism.

The University of Birmingham Department of Primary Care Clinical Sciences (Birmingham, UK), Thrombosis Research Group-Brigham and Women's Hospital (Boston, Massachusetts, USA) and AIXIAL (Paris, France). Baseline data were captured at enrolment using an electronic case report form (eCRF) designed by Dendrite Clinical Systems (Henley-on-Thames, UK). TRI oversaw the completeness and accuracy of the data, as well as data queries to study sites. A 20% portion of all eCRFs were monitored against source documentation. An electronic audit trail existed for all data modifications, and critical variables were subjected to further audits.<sup>7 8</sup> Data for components of the CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) and GARFIELD-AF risk stratification schemes were collected and calculated retrospectively.<sup>9–12</sup> Fluctuations in international normalised ratio were excluded from HAS-BLED score calculations. Follow-up data were collected at 4-month intervals up to 24 months. Data for this report were extracted from the study database on 30 June 2019.

Chronic kidney disease was classified according to National Kidney Foundation guidelines: moderate-to-severe (stages 3–5), mild (stages 1 and 2) or none. Ethnicity was classified by the investigator in agreement with the patient. Vascular disease was defined as peripheral artery disease and/or coronary artery disease. The CHADS<sub>2</sub> scores were calculated using element definitions as applied in the respective original ARISTOTLE and ROCKET AF trials. The GARFIELD-AF risk scores for 2-year risk of mortality, non-haemorrhagic stroke/SE and major bleeding in newly diagnosed non-valvular AF patients were derived using their originally reported coefficients.<sup>13</sup>

## Outcomes

The primary efficacy outcome was the composite of stroke (haemorrhagic, ischaemic or unknown type) and systemic

embolism (SE). The secondary efficacy outcome was all-cause mortality. The primary safety outcome was major bleeding characterised by one or more of the following symptoms as defined by the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis: clinically overt bleeding associated with a fall in haemoglobin of  $\geq 2$  g/dL, associated with transfusion of packed red blood cells or whole blood, bleeding with fatal outcome or bleeding in a critical site—namely intracranial (spontaneous intracerebral, intraventricular, subarachnoidal, subdural, epidural), intraspinal, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal.<sup>14</sup> Clinical events were defined prior to patient enrolment.<sup>7</sup>

## Landmark trial eligibility

Review of the protocols for ARISTOTLE and ROCKET AF identified 8 distinct inclusion and 49 exclusion criteria across both trials (online supplemental table S1).<sup>5 6</sup> All of the inclusion criteria in both trials, and many of their exclusion criteria, could be matched with GARFIELD-AF eCRFs or were operationalised where possible as described in the table footnotes. GARFIELD-AF patients were considered eligible for ARISTOTLE or ROCKET AF if one or more trial inclusion criteria and no exclusion criteria were present at baseline.

## Statistical analysis

Frequencies and percentages are reported to summarise categorical variables, and medians and IQR for continuous variables.

Unadjusted event rates for outcomes of interest were calculated using Poisson regression and presented per 100 person-years with corresponding 95% CIs. Propensity scores of apixaban versus VKA and of rivaroxaban versus VKA were generated using logistic regression. Included confounders are shown in online supplemental table S2. These scores were applied as overlap weights to Cox proportional hazards models to obtain the adjusted HRs

**Table 2** Baseline characteristics for ROCKET AF trial eligible patients by OAC treatment at baseline

Baseline characteristics	Treatment at baseline		
	Apixaban (n=1612)	Rivaroxaban (N=2005)	VKA (N=4368)
Female sex, n (%)	793 (49.2)	949 (47.3)	2072 (47.4)
Age, median (Q1; Q3), years	78.0 (73.0; 82.0)	76.0 (70.0; 81.0)	75.0 (66.0; 79.0)
Ethnicity, n (%)			
Caucasian	899 (57.2)	1389 (70.5)	2930 (68.3)
Hispanic/Latino	50 (3.2)	137 (7.0)	405 (9.4)
Asian	605 (38.5)	413 (21.0)	862 (20.1)
Afro-Caribbean/mixed/other	19 (1.2)	31 (1.6)	94 (2.2)
Body mass index, median (Q1; Q3), kg/m <sup>2</sup>	25.7 (23.1; 29.3)	27.5 (24.2; 31.2)	27.6 (24.5; 31.7)
Systolic blood pressure, median (Q1; Q3), mm Hg	130.0 (120.0; 141.0)	132.0 (120.0; 142.0)	130.0 (120.0; 142.0)
Diastolic blood pressure, median (Q1; Q3), mm Hg	78.0 (70.0; 83.0)	80.0 (70.0; 85.0)	80.0 (70.0; 85.0)
Pulse, median (Q1; Q3), bpm	82.0 (70.0; 100.0)	82.0 (70.0; 100.0)	83.0 (71.0; 100.0)
Type of atrial fibrillation, n (%)			
Permanent	254 (15.8)	327 (16.3)	878 (20.1)
Persistent	250 (15.5)	294 (14.7)	669 (15.3)
Paroxysmal	580 (36.0)	602 (30.0)	891 (20.4)
New onset (unclassified)	528 (32.8)	782 (39.0)	1930 (44.2)
Care setting specialty at diagnosis, n (%)			
Internal medicine/neurology/geriatrics	351 (21.8)	438 (21.8)	895 (20.5)
Cardiology	1123 (69.7)	1331 (66.4)	2694 (61.7)
Primary care/general practice	138 (8.6)	236 (11.8)	779 (17.8)
Care setting location at diagnosis, n (%)			
Hospital	705 (43.7)	918 (45.8)	2518 (57.6)
Office/anticoagulation clinic/thrombosis centre	781 (48.4)	926 (46.2)	1419 (32.5)
Emergency room	126 (7.8)	161 (8.0)	431 (9.9)
Medical history, n (%)			
Heart failure	423 (26.2)	594 (29.6)	1353 (31.0)
Acute coronary syndromes	156 (9.7)	211 (10.6)	486 (11.2)
Vascular disease*	339 (21.3)	512 (25.8)	1153 (26.7)
Carotid occlusive disease	65 (4.1)	60 (3.1)	110 (2.6)
VTE	30 (1.9)	54 (2.7)	117 (2.7)
Prior stroke/TIA/SE	329 (20.6)	324 (16.3)	758 (17.5)
Hypertension	1338 (83.2)	1715 (85.6)	3698 (84.9)
Hypercholesterolaemia	712 (44.9)	955 (49.4)	1993 (47.8)
Diabetes	495 (30.7)	712 (35.5)	1629 (37.3)
Moderate to severe CKD	161 (10.4)	201 (10.4)	293 (7.2)
Current smoker, n (%)	88 (6.1)	154 (8.5)	360 (9.0)
AP treatment, n (%)	251 (15.8)	328 (16.7)	994 (22.8)
CHADS2 score, median (Q1; Q3)	2.0 (2.0; 3.0)	2.0 (2.0; 3.0)	2.0 (2.0; 3.0)
CHADS2 score 0–1, n (%)	0 (0.0)	0 (0.0)	0 (0.0)
CHADS2 score 2, n (%)	915 (57.4)	1208 (60.7)	2726 (63.0)
CHADS2 score ≥3, n (%)	679 (42.6)	783 (39.3)	1600 (37.0)
CHA2DS2-VASc score, median (Q1; Q3)	4.0 (3.0; 5.0)	4.0 (3.0; 5.0)	4.0 (3.0; 5.0)
HAS-BLED score†, median (Q1; Q3)	1.0 (1.0; 2.0)	1.0 (1.0; 2.0)	1.0 (1.0; 2.0)
GARFIELD-AF mortality score‡§, median (Q1; Q3)	5.6 (3.7; 8.8)	5.6 (3.6; 8.5)	6.0 (4.0; 8.8)

Continued

Table 2 Continued

Baseline characteristics	Treatment at baseline		
	Apixaban (n=1612)	Rivaroxaban (N=2005)	VKA (N=4368)
GARFIELD-AF stroke score <sup>†</sup> , median (Q1; Q3)	1.5 (1.2; 2.1)	1.5 (1.2; 1.9)	1.7 (1.3; 2.1)
GARFIELD-AF bleeding score <sup>**</sup> , median (Q1; Q3)	1.9 (1.4; 2.4)	1.8 (1.4; 2.3)	2.3 (1.7; 2.9)

\*Defined as peripheral artery disease and/or coronary artery disease.

†The risk factor 'labile INRs' is not included in the HAS-BLED score as it is not collected at baseline. As a result, the maximum HAS-BLED score at baseline is 8 points (not 9).

‡Represents the expected probability of dying within 2 years follow-up.

§The GARFIELD-AF risk scores use different coefficients for NOAC and VKA treatment, leading to higher estimated risk in VKA users versus NOAC users with the same baseline characteristics. The scores are not impacted by the type of NOAC.

¶Represents the expected probability of developing a non-haemorrhagic stroke/SE within 2 years follow-up.

\*\*Represents the expected probability of developing a major bleeding within 2 years follow-up.

AP, antiplatelet; CKD, chronic kidney disease; GARFIELD, Global Anticoagulant Registry in the Field; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; INR, international normalised ratio; NOAC, non-vitamin K oral antagonist; ROCKET, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial; SE, systemic embolism; TIA, transient ischaemic attack; VKA, vitamin K antagonist; VTE, venous thromboembolism.

with 95% CIs for each NOAC versus VKA comparison, selecting for ARISTOTLE and ROCKET AF criteria.<sup>15 16</sup> Time-to-event analyses included patients from time of enrolment until the outcome of interest, loss to follow-up or 2 years of follow-up, whichever came first.

Treatment was defined as the first treatment received at the time of enrolment, approximating 'intention-to-treat'. Only cases with complete data for each covariate were presented in descriptive tables. The percentages of missing data per variable are shown in online supplemental table S3. Multiple imputation was applied for the comparative effectiveness analyses. Values missing from the patients' baseline covariates were imputed with multivariate imputation by chained equations. SEs were obtained by combining estimates across five imputed databases. Data analysis was carried out using SAS Enterprise Guide vV.8.2 (SAS InstituteA).

## RESULTS

All inclusion criteria and a number of key exclusion criteria of both trials were matched. Among the trial exclusion criteria that could not be verified from GARFIELD-AF data, a considerable number were either already excluded from GARFIELD-AF (eg, reversible cause for AF) or clinically unlikely to have been incorporated in a database of real-world newly diagnosed AF patients treated with OAC (eg, planned or recent major surgery, or active or recent major bleeding—see online supplemental table S1 and footnotes). Among GARFIELD-AF patients who met the trial inclusion and exclusion criteria for ARISTOTLE, 2570 were taking apixaban, 3560 rivaroxaban and 8005 VKAs. For ROCKET AF, the equivalent patient numbers were 1612, 2005 and 4368, respectively (figure 1).

Table 1 shows the baseline characteristics of OAC users eligible for ARISTOTLE. Apixaban users were older than those on rivaroxaban or VKA (median age 76, 73 and 71 years, respectively). Apixaban users also had the highest

median CHA<sub>2</sub>DS<sub>2</sub>-VASc score (4.0 vs 3.0 for rivaroxaban and VKA), and the largest proportion of patients with a CHADS<sub>2</sub> score ≥3 (28.7%, 24.4% and 25.5%, respectively). HAS-BLED scores were similarly distributed among all groups. The 2-year risks for mortality, stroke and bleeding as per the GARFIELD-AF scores were highest in VKA users, followed by participants on apixaban and rivaroxaban.

The median age among ROCKET AF-eligible apixaban, rivaroxaban and VKA users followed the same trend (78 vs 76 and 75 years, respectively) as seen above for patients selected according to ARISTOTLE criteria (table 2). Median CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED scores were similar between all OAC groups. However, the proportion of patients with a CHADS<sub>2</sub> score ≥3 was lower among those on VKA than in those on apixaban or rivaroxaban (37.0% vs 42.6% and 39.3%, respectively). As in the ARISTOTLE-eligible patients above, median GARFIELD-AF risk scores for mortality, stroke and bleeding were numerically higher for VKA than for apixaban or rivaroxaban users.

## Comparative effectiveness analyses

VKA users had the highest crude event rates per 100 person-years for all outcomes in ARISTOTLE as well as ROCKET AF-based analyses. In addition, event rates were generally lower in patients on apixaban compared with rivaroxaban, regardless of trial criteria (table 3). However, after propensity score weighting, there were no substantial differences regarding the effectiveness of NOAC versus VKA, or their relative effectiveness in patients selected according to ARISTOTLE versus ROCKET AF criteria (figure 2). However, the use of apixaban was associated with a significantly reduced risk of stroke/SE compared with VKA in ARISTOTLE-eligible participants (HR 0.57; 95% CI 0.34 to 0.94) while no reduction was observed with rivaroxaban (HR 0.98; 95% CI 0.68 to 1.40). When

**Table 3** Crude event rates (per 100 person-years) within 2-year follow-up for patients eligible for ARISTOTLE and ROCKET AF by baseline OAC treatment

Outcome	Apixaban			Rivaroxaban			VKA		
	N total	N events	Rate (95% CI)	N total	N events	Rate (95% CI)	N total	N events	Rate (95% CI)
Stroke/SE	2570	32	0.7 (0.5 to 0.9)	3560	57	0.8 (0.6 to 1.1)	8005	152	1.0 (0.9 to 1.2)
Major bleeding	2570	40	0.8 (0.6 to 1.1)	3560	66	1.0 (0.8 to 1.2)	8005	165	1.1 (0.9 to 1.3)
All-cause mortality	2570	151	3.0 (2.6 to 3.6)	3560	208	3.0 (2.7 to 3.5)	8005	566	3.8 (3.5 to 4.1)
Stroke/SE	1612	28	0.9 (0.6 to 1.3)	2005	39	1.0 (0.8 to 1.4)	4368	90	1.1 (0.9 to 1.4)
Major bleeding	1612	27	0.9 (0.6 to 1.3)	2005	44	1.2 (0.9 to 1.6)	4368	98	1.2 (1.0 to 1.5)
All-cause mortality	1612	119	3.9 (3.2 to 4.6)	2005	158	4.2 (3.6 to 4.9)	4368	371	4.5 (4.1 to 5.0)

ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; OAC, oral anticoagulation; ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; SE, systemic embolism; VKA, vitamin K antagonist.

selecting for ROCKET AF criteria, no significant associations were observed, with safety and efficacy versus VKA being similar between the two NOACs. All confounders in the propensity score were balanced between NOAC and VKA after weighting (online supplemental figures S1–S4), indicating that the emulated ‘treatment arms’ were comparable for all considered confounders after the weighting scheme was applied.


## DISCUSSION

We used a novel approach to assess the potential influence of trial inclusion criteria on reported safety and efficacy by emulating two landmark NOAC versus VKA trials in real-world AF patients. Patient baseline characteristics and 2-year follow-up matched conditions of the ARISTOTLE and ROCKET AF landmark studies.<sup>5,6</sup> The main finding is that the relative effectiveness of all three OACs was similar when applying the ROCKET AF criteria, and thus selecting patients at a higher risk of stroke. By contrast, when the more inclusive ARISTOTLE criteria were applied, apixaban, and to a lesser extent rivaroxaban, demonstrated significant clinical benefits in terms of stroke/SE risk compared with VKA. These findings are not intended to guide the prescription of specific OACs in stroke prophylaxis, rather they highlight the importance of selection criteria when designing and interpreting clinical trials.

The adjusted HRs in observational data showed considerable overlap with the results of the original trials in all selected outcomes. Differences in the risk of selected outcomes between ROCKET AF and our emulation of the trial could be due to the fact that the trial design limited the number of recruited low-risk patients. We did not apply the same restrictions to the GARFIELD-AF dataset because doing so would have further reduced the number of eligible rivaroxaban users, and thereby the statistical power in our analysis.

Interestingly, applying the ARISTOTLE selection criteria to the GARFIELD-AF registry did not replicate the original trial’s finding that apixaban reduces major bleeding compared with VKA.<sup>5</sup> This discrepancy might be due to differences in the proportion of patients with moderate-to-severe renal impairment. In our cohort, 8.8% of apixaban-treated and 6.3% of VKA-treated patients had moderate-to-severe renal impairment, compared with approximately 16.5% in both arms of ARISTOTLE. Subgroup analysis of ARISTOTLE showed apixaban’s protection against major bleeding varied according to renal impairment level, benefiting those with moderate-to-severe impairment but not those with no impairment. Therefore, the lower proportion of patients with significant renal impairment in our study could partially explain the lack of association between apixaban and major bleeding.

Randomised clinical trials remain the gold standard of medical research. However, results of NOAC versus VKA trials are difficult to compare due to markedly different



**Figure 2** Propensity-score weighted HRs comparing apixaban or rivaroxaban versus VKA as reference. Shown are HRs for selected outcomes through 2 years of follow-up in the study populations selected using ARISTOTLE and ROCKET AF criteria. HR obtained using an overlap-weighted Cox model that included the following variables in the weighting scheme: country and cohort enrolment, sex, age, ethnicity, type of AF, care setting specialty and location, congestive heart failure, acute coronary syndromes, vascular disease, carotid occlusive disease, prior stroke/transient ischaemic attack/SE, prior bleeding, VTE, hypertension, hypercholesterolaemia, diabetes, moderate to severe chronic kidney disease, hyperthyroidism, hypothyroidism, current smoking, heavy alcohol consumption, body mass index, heart rate, systolic and diastolic blood pressure at diagnosis, and baseline antiplatelet use. AF, atrial fibrillation; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events; NOAC, non-vitamin K antagonist; ROCKET, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial; SE, systemic embolism; VKA, vitamin K antagonist; VTE, venous thromboembolism.

baseline characteristics of the participants, as outlined by numerous reports.<sup>4 17–20</sup> When direct comparisons through randomised trials are unavailable, high-quality observational data are required for assessing relative drug performance.<sup>21 22</sup> The GARFIELD-AF registry contains extensive data for baseline characteristics and outcomes over a 2-year follow-up period, similar to the original ARISTOTLE and ROCKET AF trials. This enabled a valid emulation of both trials' inclusion and exclusion criteria.

Several studies suggest that NOACs might have different risk/benefit profiles in AF patients, especially when not at a high risk of stroke. The largest and most comprehensive observational study comparing NOACs in patients with AF found that apixaban was associated with the lowest risk for gastrointestinal bleeding among all NOACs, but similar rates of ischaemic stroke or SE and intracranial haemorrhage. Estimated risks among users of apixaban versus rivaroxaban for gastrointestinal bleeding (HR 0.72, 95% CI 0.66 to 0.79) and ischaemic stroke/SE (HR 0.89, 95% CI 0.78 to 1.02) were in line with earlier large observational studies and meta-analysis.<sup>23</sup> Ray *et al*, with a larger number of patients on apixaban and rivaroxaban, provided more precise estimates for intracranial haemorrhage (HR 0.68, 95% CI 0.59 to 0.77) and all-cause mortality (HR 0.94, 95% CI 0.92 to 0.98).<sup>21</sup> A method for

indirectly comparing NOACs is network meta-analysis of randomised controlled trials. A systematic review of 22 such studies concluded that no significant difference existed between apixaban and rivaroxaban regarding the risk for stroke/SE, but that apixaban had a lower risk for major bleeding.<sup>24</sup>

As mentioned above, these results need to be interpreted cautiously due to differences between the designs of the original trials.<sup>4</sup> Interestingly, one meta-analysis observed that among very high-risk patients in ARISTOTLE and ROCKET AF (CHADS<sub>2</sub> score  $\geq 3$ ) the risks of stroke or death were similar, irrespective of the NOAC used. However, unlike in our ROCKET AF selected patients, significantly fewer major haemorrhage events occurred in the high-risk apixaban compared with rivaroxaban users.<sup>25</sup>

The GARFIELD-AF registry's active enrolment coincided with the emergence of NOACs for use in non-valvular AF. Previous work in the registry confirmed safety and efficacy of NOACs versus VKA overall, and in subgroup populations of newly diagnosed AF patients.<sup>26 27</sup>

### Strengths and limitations

The main strengths of this analysis arise from the GARFIELD-AF registry as the largest worldwide



prospective observational cohort of newly diagnosed AF patients. A detailed and highly complete follow-up allowed for the assessment of 2-year outcomes and emulation of two randomised trials in the same dataset. Studies with smaller sample sizes or shorter follow-up can be insufficiently powered to detect differences in the rates of rare events between treatment groups.

The extensive baseline investigation enabled assessment of all inclusion, as well as the main exclusion criteria of the ARISTOTLE and ROCKET AF trials. It also allowed for a detailed presentation of baseline characteristics, which showed the effect of different eligibility criteria on comorbidity and risk profiles of eligible participants. Further strengths are the use of propensity score overlap weights to ensure comparisons of NOAC versus VKA in patients with similar baseline properties, and use of similar outcome definitions to compare results, unlike the different definitions used in the original trials.<sup>4-6</sup>

This work had several limitations. Treatment was defined as first OAC received, analogous to an intention-to-treat analysis, not accounting for non-recommended dosing, treatment switches or cessation. Not all exclusion criteria defined in the original ARISTOTLE and ROCKET AF protocols could be operationalised in the GARFIELD-AF dataset. However, the main reasons for non-operationalised trial exclusion were clinically established contraindications to any OAC, for example, planned major surgery or recent stroke or major bleeding. Therefore, it was unlikely that such patients were enrolled in GARFIELD-AF and thus wrongfully included in the current analysis.

The geographical catchment of the trials differed from that of GARFIELD-AF which covered over 30 countries. We previously observed geographical variation in the outcomes of OAC treatment in AF patients that was not explained by baseline risk factors and likely due to regional differences in clinical practice, including the management of comorbidities.<sup>28</sup> Patients of black African ancestry were likely underrepresented in all of the studies.

Due to the more stringent selection criteria for ROCKET AF, this trial's emulation contained fewer patients, resulting in wider CIs and less certainty in the observed trends. Unlike ROCKET AF, we did not restrict the proportion of patients with CHADS<sub>2</sub> score ≤2 to a maximum of 10% of the sample. Consequently, the overall cardiovascular risk in the population of the emulated trial was lower than in the original trial.

Fourth, we did not include GARFIELD-AF participants on dabigatran or edoxaban at baseline. The registry contained few edoxaban users because this NOAC had not yet been widely introduced during GARFIELD-AF enrolment. As for dabigatran, its landmark trial reported separate results for the doses 150 and 110 mg.<sup>29</sup> However, the GARFIELD-AF registry contained too few dabigatran users to allow for stratification into separate dabigatran dosage arms in our analyses.

Finally, although we adjusted for an extensive list of confounding factors, in an observational study, the

possibility of unmeasured confounding cannot be ruled out. Therefore, definite conclusions regarding superiority of any NOAC will require direct comparison in carefully designed randomised trials.

## CONCLUSION

Apixaban and rivaroxaban had similar results versus VKA when emulating trials in higher-risk patients using ROCKET AF criteria. When the more inclusive ARISTOTLE criteria were applied, apixaban demonstrated clinical benefits compared with VKA in terms of reducing the risk of stroke/SE. These observations provide insights into the role of trial inclusion criteria in trial result interpretation and underline the importance of high-quality observational data for assessment of relative drug performance in populations who are treated according to local practices and not in the confines of a randomised trial. Such randomised trials will be needed to inform policy decisions for clinicians who wish to initiate an NOAC in their recently diagnosed AF patients.

## Author affiliations

<sup>1</sup>Department of General Practice, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands

<sup>2</sup>Thrombosis Research Institute, London, UK

<sup>3</sup>Amsterdam Public Health, Personalized Medicine, Amsterdam, Netherlands

<sup>4</sup>Cardiology, St George's Hospital, London, Ohio, USA

<sup>5</sup>Cardiology, Memorial Ankara Hospital, Ankara, Turkey

<sup>6</sup>University of the Witwatersrand Johannesburg, Johannesburg, South Africa

<sup>7</sup>Sir Ganga Ram Hospital, New Delhi, India

<sup>8</sup>Cardiology, National University Heart Centre, Singapore

<sup>9</sup>Medicine Alfred Hospital, Monash University, Melbourne, Victoria, Australia

<sup>10</sup>Tokai University School of Medicine Graduate School of Medicine, Isehara, Kanagawa, Japan

<sup>11</sup>Haemostasis and Thrombosis Research Group, Institute for Experimental Oncology and Therapy Research, Formerly Technical University Munich, Munich, Germany

<sup>12</sup>Cardiology, University of Edinburgh and Royal Infirmary, Edinburgh, UK

<sup>13</sup>University Hospital Motol, Prague, Czech Republic

<sup>14</sup>Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands

<sup>15</sup>Department of Surgery, University College London, London, UK

X Shinya Goto @antithrombosis

**Acknowledgements** We would like to thank the physicians, nurses and patients involved in the GARFIELD-AF registry, and Thomas Weissensteiner and Hamish Aitken-Buck (Thrombosis Research Institute, London, UK) for writing and editorial support.

**Contributors** All authors fulfilled the criteria under The International Committee of Medical Journal Editors Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations 2019). JCLH was the guarantor of this work.

**Funding** This work was supported by the Thrombosis Research Institute (London, UK). The GARFIELD-AF registry was sponsored by an unrestricted grant awarded by Bayer AG (Berlin, Germany) to the Thrombosis Research Institute.

**Competing interests** JC reports institutional grants and personal fees from Bayer, Boehringer Ingelheim, Pfizer/BMS and Daiichi Sankyo and personal fees from Portola. KP has consultancies with Johnson & Johnson, Element Science, Artivion and Novartis. AO received a research grant from Pfizer and is Steering Committee Member and National Coordinator of the ENGAGE-AF (TIMI 48) study. B.F.J. received speaker honoraria from Boehringer, Sanofi, Aspen, Pfizer, Takeda and Astra Zeneca. Jitendra Pal Singh Sawhney reports professional/advisory fees outside the submitted work from Pfizer, Astra Zeneca, Novartis, Sanofi, Torrent and Lupin. TWL has received research support from Bayer, Boehringer Ingelheim and Pfizer. HG

received honoraria from Bayer Australia, Eli Lilly Australia, Pfizer Australia and BMS Australia. Shinya Goto was a recipient of quality personal fees from Jansen and Antos, and Phillips, fees from the American Heart Association as an Associate Editor for Circulation, and Steering Committee fees from Duke University. SH received personal fees from Bayer, BMS, Daiichi Sankyo, Pfizer, Sanofi. KAAF reports grants and personal fees from Bayer/Janssen and Astra Zeneca. PJ has served as a consultant or on an advisory board for Bayer, Boehringer Ingelheim, and Novartis. FV has received grants from Bayer Healthcare, and personal fees from Bayer Healthcare, BMS/Pfizer, Daiichi-Sankyo, and Boehringer-Ingelheim. AKK received personal fees and grants from Bayer AG, Sanofi S.A. and Anthos Therapeutics. JCLH, SV and REH report no conflicts of interest.

**Patient consent for publication** Not applicable.

**Ethics approval** The GARFIELD-AF registry protocol was approved by a hospital-based institutional review board, an independent ethics committee and individual study sites. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Pharmacoeconomic and Clinical Practice Guidelines and local regulatory requirements. Written consent was obtained from all study participants, and anonymity and confidentiality were maintained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Requests for patient level data can be made to SV, head of statistics at the Thrombosis Research Institute (svirdone@tri-london.ac.uk). These requests should include a protocol summary and a summary of the statistical analysis plan. The request will be reviewed by the data sharing committee for approval and next steps will be discussed with the requestor.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.


#### ORCID iD

Jelle C L Himmelreich <http://orcid.org/0000-0003-0430-1583>

#### REFERENCES


- Hindricks G, Potpara T, Dagres N. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic surgery (EACTS). *Eur Heart J* 2021;42:546–7.
- January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart Association task force on clinical practice guidelines and the heart rhythm society. *J Am Coll Cardiol* 2019;74:104–32.
- Perry M, Kemmis Betty S, Downes N, et al. Atrial fibrillation: diagnosis and management-summary of NICE guidance. *BMJ* 2021;373:1150.
- Camm AJ, Fox KAA, Peterson E. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. *Europace* 2018;20:1–11.
- Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981–92.
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in Nonvalvular atrial fibrillation. *N Engl J Med* 2011;365:883–91.
- Kakkar AK, Mueller I, Bassand J-P, et al. International longitudinal Registry of patients with atrial fibrillation at risk of stroke: global anticoagulant registry in the FIELD (GARFIELD). *Am Heart J* 2012;163:13–9.
- Fox KAA, Gersh BJ, Traore S, et al. Evolving quality standards for large-scale registries: the GARFIELD-AF experience. *Eur Heart J Qual Care Clin Outcomes* 2017;3:114–22.
- Lip GYH, Nieuwlaet R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. *Chest* 2010;137:263–72.
- Pisters R, Lane DA, Nieuwlaet R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation the Euro head survey. *Chest* 2010;138:1093–100.
- Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. *BMJ Open* 2017;7:e017157.
- Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. *JAMA* 2001;285:2864–70.
- Fox KAA, Virdone S, Pieper KS, et al. GARFIELD-AF risk score for mortality, stroke and bleeding within 2 years in patients with atrial fibrillation. *Eur Heart J Qual Care Clin Outcomes* 2022;8:214–27.
- Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. *J Thromb Haemost* 2010;8:202–4.
- Thomas LE, Li F, Pencina MJ. Overlap weighting a propensity score method that mimics attributes of a randomized clinical trial. *JAMA J Am Med Assoc* 2020;323:2417–8.
- Farjat AE, Virdone S, Thomas LE, et al. The importance of the design of observational studies in comparative effectiveness research: lessons from the GARFIELD-AF and ORBIT-AF registries. *Am Heart J* 2022;243:110–21.
- Lee S, Monz BU, Clemens A, et al. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United kingdom: a cross-sectional analysis using the general practice research database. *BMJ Open* 2012;2:e001768.
- Hägg L, Johansson C, Jansson J-H, et al. External validity of the ARISTOTLE trial in real-life atrial fibrillation patients. *Cardiovasc Ther* 2014;32:214–8.
- Desmaele S, Steurbaut S, Cornu P, et al. Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients *Eur J Clin Pharmacol* 2016;72:1125–34.
- Fanning L, Iiomäki J, Bell JS, et al. The Representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. *Eur J Clin Pharmacol* 2017;73:1427–36.
- Ray WA, Chung CP, Stein CM, et al. Association of Rivaroxaban vs Apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. *JAMA* 2021;326:2395–404.
- Camm AJ, Fox KAA. “Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants”. *Open Heart* 2018;5:e000788.
- Lau WCY, Torre CO, Man KKC, et al. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study. *Ann Intern Med* 2022;175:1515–24.
- Cohen AT, Hill NR, Luo X, et al. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with direct oral anticoagulants. *Int J Cardiol* 2018;269:174–81.
- Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes* 2012;5:480–6.
- Camm AJ, Fox KAA, Virdone S, et al. Comparative effectiveness of oral anticoagulants in everyday practice. *Heart* 2021;107:962–70.
- Haas S, Camm AJ, Bassand J-P, et al. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. *Am Heart J* 2019;213:35–46.
- Fox KAA, Virdone S, Bassand J-P, et al. Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF Registry. *BMJ Open* 2022;12:e049933.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139–51.

**Supplementary Figure S1.** Balance of variables associated with apixaban treatment in reference to VKA treatment at baseline before and after propensity score weighting, in apixaban and VKA users eligible for ARISTOTLE




AF, atrial fibrillation; AP, antiplatelet; BMI, body mass index; CKD, chronic kidney disease; SE, systemic embolism; TIA, transient ischaemic attack; VTE, venous thromboembolism

**Supplementary Figure S2.** Balance of variables associated with rivaroxaban treatment in reference to VKA treatment at baseline before and after propensity score weighting, in apixaban and VKA users eligible for ARISTOTLE




AF, atrial fibrillation; AP, antiplatelet; BMI, body mass index; CKD, chronic kidney disease; SE, systemic embolism; TIA, transient ischaemic attack; VTE, venous thromboembolism

**Supplementary Figure S3.** Balance of variables associated with apixaban treatment in reference to VKA treatment at baseline before and after propensity score weighting, in apixaban and VKA users eligible for ROCKET AF



AF, atrial fibrillation; AP, antiplatelet; BMI, body mass index; CKD, chronic kidney disease; SE, systemic embolism; TIA, transient ischaemic attack; VTE, venous thromboembolism

**Supplementary Figure S4.** Balance of variables associated with rivaroxaban treatment in reference to VKA treatment at baseline before and after propensity score weighting, in apixaban and VKA users eligible for ROCKET AF



AF, atrial fibrillation; AP, antiplatelet; BMI, body mass index; CKD, chronic kidney disease; SE, systemic embolism; TIA, transient ischaemic attack; VTE, venous thromboembolism

**Supplementary Table S1.** Inclusion and exclusion criteria in ARISTOTLE and ROCKET

AF, and their presence and operationalisation in GARFIELD-AF

Trial criteria		ARISTOTLE	ROCKET AF
Inclusion criteria	Age	IC	IC
	Stroke, TIA or systemic embolism history	IC	IC
	Heart failure history	IC <sup>1</sup>	IC
	Hypertension history	IC	IC <sup>2</sup>
	Hypertension treatment	IC <sup>3</sup>	IC <sup>4</sup>
	Diabetes mellitus history	IC	IC
	Diabetes mellitus treatment		IC <sup>5</sup>
	LVEF	IC	IC
Exclusion criteria	Reversible cause for AF	EC <sup>6</sup>	EC <sup>6</sup>
	Pregnancy or breastfeeding	EC	EC
	Uncontrolled hypertension	EC <sup>7</sup>	EC <sup>8</sup>
	Severe renal insufficiency history	EC <sup>9</sup>	EC <sup>10</sup>
	High bleeding risk	EC <sup>11</sup>	EC <sup>11</sup>
	Recent ischemic stroke	EC <sup>12</sup>	EC <sup>12</sup>
	Recent TIA		EC <sup>12</sup>
	Severe prior stroke		EC <sup>13</sup>
	Bleeding history	EC <sup>14</sup>	EC
	Recent gastrointestinal bleeding		EC
	Active internal bleeding		EC
	Planned major surgery	EC	EC
	Recent major surgery	EC	EC
	Alcohol abuse	EC	EC
	Drug abuse	EC	EC
	Simultaneous treatment with both aspirin and a thienopyridine (e.g., clopidogrel, ticlopidine)	EC	EC <sup>15</sup>
	High-dose aspirin treatment	EC <sup>16</sup>	EC <sup>16</sup>
Recent intravenous antiplatelet use		EC	
Chronic NSAID use		EC <sup>17</sup>	

Use of cytochrome P450 3A4 inhibitor		EC
Use of cytochrome P450 3A4 inducer		EC
Anaemia	EC <sup>18</sup>	EC <sup>19</sup>
Thrombocytopenia	EC <sup>20</sup>	EC <sup>21</sup>
Inability to comply with INR monitoring	EC <sup>22</sup>	EC
Heart valve disease history	EC <sup>23</sup>	EC <sup>24</sup>
Atrial myxoma or left ventricular thrombus		EC <sup>25</sup>
Contraindication to VKA		EC <sup>26</sup>
Planned cardioversion therapy		EC <sup>27</sup>
Active liver disease		EC <sup>28</sup>
Liver function tests	EC	EC
Active hepatitis A, B or C		EC
Adequate contraceptive use	EC	EC
Anticoagulation use for chronic condition	EC	
Any indication for anticoagulation other than AF		EC <sup>29</sup>
Active infective endocarditis	EC	EC
Planned AF ablation procedure	EC	
Recent use of investigational drug or device	EC	EC
Prior randomization into NOAC trial	EC	EC
Short life expectancy	EC	EC
Psychosocial reasons that make study participation impractical	EC	EC
Prisoner	EC	
Compulsorily detained for treatment of illness	EC	
Haemorrhagic disorder or bleeding diathesis		EC
Recent fibrinolytic agents use		EC <sup>17</sup>
Patients considered unreliable		EC
Known intracranial neoplasm, arteriovenous malformation, or aneurysm		EC
Known HIV history at baseline		EC
Known allergy to VKA or investigational drug		EC
Employees of the investigator or study centre		EC

Shown are the inclusion and inclusion criteria across the two landmark NOAC trials.



Highlights: green, in trial protocol and present in the registry as defined by the trial protocol; yellow, in trial protocol and can be operationalised with sufficient validity from the registry although not recorded in the registry precisely as defined by the trial protocol (see comments below for operational definition applied in the registry); red, in trial protocol but absent and cannot be operationalised with sufficient validity in the registry; grey, not part of a trial's inclusion and exclusion criteria.

AF, atrial fibrillation; ALT, alanine transaminase; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; AST, aspartate transaminase; EC, in the study as exclusion criterion; GARFIELD-AF, Global Anticoagulant Registry in the FIELD; IC, in the study as inclusion criterion; LVEF, left ventricular ejection fraction; ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; TIA, transient ischaemic attack.

<sup>1</sup> Defined in ARISTOTLE as symptomatic congestive heart failure within three months, operationalised in GARFIELD-AF as history of congestive heart failure;

<sup>2</sup> Defined in ROCKET AF as use of antihypertensive medications within six months before the screening visit or persistent systolic blood pressure above 140 mmHg or diastolic blood pressure above 90 mmHg, operationalised in GARFIELD-AF as hypertension history or use of  $\geq 2$  antihypertensive drugs at baseline;

<sup>3</sup> Defined in GARFIELD-AF as the use of  $\geq 2$  antihypertensive drugs at baseline;

<sup>4</sup> Defined in ROCKET AF as use of antihypertensive medications within six months before the screening visit, operationalised in GARFIELD-AF as use of  $\geq 2$  antihypertensive drugs at baseline;

- <sup>5</sup> Defined in ROCKET AF as use of antidiabetic medications within six months before screening visit, operationalised in GARFIELD-AF as use of antidiabetic drugs at baseline;
- <sup>6</sup> Patients with reversible cause for AF were excluded from GARFIELD-AF;
- <sup>7</sup> Defined in ARISTOTLE as persistent, uncontrolled hypertension (systolic blood pressure (SBP) >180 mm Hg, or diastolic blood pressure (DBP) >100 mmHg), operationalised in GARFIELD-AF as baseline SBP>180 or DBP>100 mmHg;
- <sup>8</sup> Defined in ROCKET AF as SBP  $\geq$ 180 mmHg or DBP  $\geq$ 100 mmHg;
- <sup>9</sup> Defined in ARISTOTLE as serum creatinine >2.5 mg/dL or a calculated creatinine clearance <25 mL/min, operationalised in GARFIELD-AF as chronic kidney disease (CKD) class IV or V;
- <sup>10</sup> Defined in ROCKET AF as calculated creatinine clearance <30 mL/min as per Cockcroft and Gault formulas at the screening visit, operationalised in GARFIELD-AF as chronic kidney disease (CKD) class IV or V;
- <sup>11</sup> Operationalised in GARFIELD-AF as history of bleeding, dementia, compliance concern of dementia or baseline GARFIELD-AF bleeding score >4% at two years;
- <sup>12</sup> Medical history element recorded in GARFIELD-AF, without date of diagnosis;
- <sup>13</sup> Defined in ROCKET AF as modified Rankin score of 4 to 5;
- <sup>14</sup> In ARISTOTLE as part of the high bleeding risk criterion, defined as increased bleeding risk that is believed to be a contraindication to oral anticoagulation (e.g. previous intracranial haemorrhage);
- <sup>15</sup> Defined in ROCKET AF as aspirin in combination with thienopyridines within five days before randomization, operationalised in GARFIELD-AF as concomitant aspirin and thienopyridine use at baseline;
- <sup>16</sup> Use of this medication was scored in GARFIELD-AF, without dosage information
- <sup>17</sup> Medication use recorded in the registry, without date of (last) usage;

- <sup>18</sup> Defined in ARISTOTLE as haemoglobin <10 g/dL, baseline laboratory test results or anaemia history were not included in the GARFIELD-AF CRF;
- <sup>19</sup> Defined in ROCKET AF as haemoglobin <10 g/dL, baseline laboratory test results or anaemia history were not included in the GARFIELD-AF CRF;
- <sup>20</sup> Defined in ARISTOTLE as platelet count  $\leq 100,000/\text{mm}^3$ , baseline laboratory test results or thrombocytopenia history were not included in the GARFIELD-AF CRF;
- <sup>21</sup> Defined in ROCKET AF as platelet count <90,000/ $\mu\text{L}$ , baseline laboratory test results or thrombocytopenia history were not included in the GARFIELD-AF CRF;
- <sup>22</sup> Operationalised in GARFIELD-AF as compliance concern of limited access to INR monitoring;
- <sup>23</sup> Defined in ARISTOTLE as mitral valve stenosis, which is not specifically recorded in GARFIELD-AF;
- <sup>24</sup> Defined in ROCKET AF as haemodynamically significant mitral valve stenosis or prosthetic heart valve (annuloplasty with or without prosthetic ring, commissurotomy and/or valvuloplasty are permitted), neither of which were specifically recorded in GARFIELD-AF;
- <sup>25</sup> Operationalised in GARFIELD-AF as presence of intracardiac thrombus;
- <sup>26</sup> Defined in GARFIELD-AF as dementia history, dementia as compliance concern, or bleeding risk, fall risk or previous bleeding event as reason not to start oral anticoagulation;
- <sup>27</sup> Operationalised in GARFIELD-AF as cardioversion at baseline or  $\leq 48$  days of registry enrolment;
- <sup>28</sup> Operationalised in GARFIELD-AF as cirrhosis history;
- <sup>29</sup> Defined in GARFIELD-AF as any prior use of vitamin K anticoagulants

**Supplementary Table S2.** Variables included in the propensity score weighting scheme. All variables were recorded at baseline

<b>General</b>	<b>Demographics</b>	<b>Vital signs</b>	<b>Medical history</b>	<b>Medication</b>
Country of enrolment	Sex	BMI		Antiplatelet use
Cohort of enrolment	Age	Heart rate	Congestive heart failure	
Care setting speciality	Ethnicity	Systolic blood pressure	Acute coronary syndromes	
Care setting location		Diastolic blood pressure	Vascular disease	
Current smoking			Carotid occlusive disease	
Heavy alcohol consumption			Prior stroke/TIA/SE	
Type of AF			Prior bleeding	
			VTE	
			Hypertension	
			Hypercholesterolemia	
			Diabetes	
			Moderate to severe CKD	
			Hyperthyroidism	
			Hypothyroidism	

All variables were assessed at baseline.

AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; SE, systemic embolism; TIA, transient ischaemic attack; VTE, venous thromboembolism.

**Supplementary Table S3.** Missingness proportion (%) for selected variables by study

population and baseline treatment

Variable	ROCKET AF trial eligible patients		ARISTOTLE trial eligible patients	
	Rivaroxaban	VKA	Apixaban	VKA
	(N = 2005)	(N = 4368)	(N = 2570)	(N = 8005)
Country	0.0	0.0	0.0	0.0
Cohort	0.0	0.0	0.0	0.0
Sex	0.0	0.0	0.0	0.0
Race/ethnicity	1.7	1.8	3.2	1.7
Type of AF	0.0	0.0	0.0	0.0
Care setting location	0.0	0.0	0.0	0.0
Care setting specialty	0.0	0.0	0.0	0.0
Heart failure	0.0	0.0	0.0	0.0
Vascular disease	1.1	1.0	1.1	1.0
ACS	0.6	0.7	0.7	0.6
Carotid occlusive disease	2.2	2.4	1.6	2.1
Prior stroke/TIA/SE	0.7	1.0	1.1	0.9
Prior bleeding	0.3	0.5	0.5	0.4
VTE	0.7	0.8	0.7	0.7
Hypertension	0.1	0.3	0.2	0.2
Hypercholesterolaemia	3.6	4.5	2.1	4.9
Diabetes	0.0	0.0	0.0	0.0
Cirrhosis	2.0	2.2	1.6	2.2
CKD	3.9	6.7	3.3	6.9
Dementia	0.8	0.5	0.8	0.6
Hyperthyroidism	2.7	3.0	2.3	3.1
Hypothyroidism	2.7	3.1	2.1	3.2
Alcohol consumption	16.1	15.1	18.9	15.0
Smoking status	9.6	8.2	11.0	7.9
Antiplatelet therapy	1.9	0.0	1.7	0.0
Age	0.0	0.0	0.0	0.0

---

SBP	5.1	7.3	5.5	6.4
DBP	5.1	7.3	5.5	6.4
Pulse	7.3	8.4	6.0	7.3
BMI	19.7	24.0	20.6	23.0

---

AF, atrial fibrillation; ACS, acute coronary syndromes; BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; SE, systemic embolism; SBP, systolic blood pressure; TIA, transient ischemic attack; VTE, venous thromboembolism.

AF, atrial fibrillation; ACS, acute coronary syndromes; BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; SE, systemic embolism; SBP, systolic blood pressure; TIA, transient ischemic attack; VTE, venous thromboembolism.

**APPENDIX: Complete list of GARFIELD-AF Principle Investigators****Global Steering Committee**

Ajay K. Kakkar (UK) (Chair), Jean-Pierre Bassand (France), A. John Camm (UK), David A. Fitzmaurice (UK), Samuel Z. Goldhaber (USA), Shinya Goto (Japan), Sylvia Haas (Germany), Werner Hacke (Germany), Lorenzo G. Mantovani (Italy), Frank Misselwitz (Germany), Karen S. Pieper (USA), Alexander G.G. Turpie (Canada), Martin van Eickels (Germany), Freek W.A. Verheugt (the Netherlands).

**Publications Committee**

A. John Camm (UK) (Chair), Jean-Pierre Bassand (France), Samuel Z. Goldhaber (USA), Sylvia Haas (Germany), Gloria Kayani (UK), Lorenzo G. Mantovani (Italy).

**Audit Committee**

Keith A.A. Fox (UK), Bernard J. Gersh (USA).

**GARFIELD-AF National Coordinators**

Hector Lucas Luciardi (Argentina), Harry Gibbs (Australia), Marianne Brodmann (Austria), Frank Cools (Belgium), Antonio Carlos Pereira Barretto (Brazil), Stuart J. Connolly, Alex Spyropoulos, John Eikelboom (Canada), Ramon Corbalan (Chile), Dayi Hu (China), Petr Jansky (Czech Republic), Jørn Dalsgaard Nielsen (Denmark), Hany Ragy (Egypt), Pekka Raatikainen (Finland), Jean-Yves Le Heuzey (France), Harald Darius (Germany), Matyas Keltai (Hungary), Sanjay Kakkar and Jitendra Pal Singh Sawhney (India), Giancarlo Agnelli and Giuseppe Ambrosio (Italy), Yukihiro Koretsune (Japan), Carlos Jerjes Sánchez Díaz (Mexico), Hugo ten Cate (the Netherlands), Dan Atar (Norway), Janina Stepinska (Poland), Elizaveta Panchenko (Russia), Toon Wei Lim (Singapore), Barry Jacobson (South Africa), Seil Oh (South Korea), Xavier Viñolas (Spain), Marten Rosenqvist (Sweden), Jan Steffel (Switzerland), Pantep Anchaisuksiri (Thailand), Ali Oto (Turkey), Alex Parkhomenko (Ukraine), Wael Al Mahmeed (United Arab Emirates), David Fitzmaurice (UK), Samuel Z. Goldhaber (USA).

**GARFIELD-AF National Investigators:****China**

Dayi Hu, Yihong Sun, Lei Li, Wenling Liu, Yuanfeng Gao, Kangning Chen, Hong Zhai, Yusheng Zhao, Ran Zhang, Huaiqin Zhang, Xiao Chen, Jiyan Chen, Tingting Liu, Kan Wang, Xiaosheng Hu, Shiping Cao, Qiong Zhan, Jingshan Yang, Xingfu Huang, Daowen Wang, Ting Yu, Xiaoxue Yan, Yang Bai, Yuejin Yang, Xuesi Wu Qian Zhang, Zhicheng Jing, Xiaoliang Luo, Zhicheng Jing, Xiaojin Gao, Weihua Li, Wuyang Zheng, Hui Li, Yanhong Li, Hongying Yu, Tiebing Song, Shanshan Feng, Yuehui Yin, Xianbin Lan, Bei Zhou; Guizhou Tao, Ge Tian, Xiaojing Shi, Ping Yang, Bing Li, Yingmin Chen, Shenghu He, Yi Zhang, Yong Wang, Jing Li, Guosheng Fu, Yang Ye, Xia Sheng, Xin Li, Tongguo Wu, Jin Chen, Cancan Zuo, Xiaobi Guo, Xiaoshu Cheng, Qinmei Xiong, Aijuan Xu, Juxiang Li, Jianhua Yu; Xiaowei Yan, Ruiyi Xu, Xue Lin; Ruiping Zhao, Yangyang Liu, Rina Wu, Moshui Chen, Tianyi Ma, Yixue Zhang, Zhihong Zhou, Xiaoi He, Longgen Xiong, Li Wang, Chuanfang Cheng, Chengfeng Luo, Zhicheng Lu, Ping Chen, Ying Wang, Yang Jiao, Xinyi Zhu, Ying Guo, Qinghua Fu, Qin Yang, Na Li, Jianqiang Peng, Qiong Xie, Li Xue, Weina Guo, Ruhua He, Lin Chen, Guoshan Zhang, Zhiming Yang, Fengzhi Wang, Shuai Feng, Lin Yang, Jinxiu Zhang, Chunlin Bai.



**India**

Praveen Jadhavm, Priyanka Dhakrao, Deepak Ghumare, Raghava Sarma, Naga Malleswara Rao, Govind Kulkarni, Unnati Joshi, Bhakti Deshpande, Shankar G Panse, Anjali Sable, Amol Lawande, Prakash Chandwani, Mahendra Sharma, Rasesh Atulbhai Pothiwala, Dhrumi Shah, Nehal Sadhu, Pratik Dwivedi, Mohanan Padinhare Purayil, Divin Davies, Manoj Earath, Kamaldeep Chawla, Amish Ganatra, Khyati Patel, Veerappa Annasaheb Kothiwale, James Kot, Kinjal Shah, Vineeta Dhyani, Bagirath Raghuraman, Sudheer Garapati, Ayyappa N, Subramani Krishnappa, Vinod Madan Vijan, Mahesh Dargude, Jitendra Sawhney, Somya Duhan, Ganapathi Bantwal, Sudha Suresh, Aziz Khan, Puja Sherke, Satish Giradkar, Kajal Gaikwad, Reshma Kohade, Alka Gedam, Ramdhan Meena, Jugal Gupta, Vipin Jain, Shweta Paliwal, Manojkumar Chopada, Bhushan Suryawanshi, Priyanka More, Anand Rokade, Sunitha Abraham, Rajendran Karthikeyan, Anusha Kotha, Vikas Bisne, Bhowari Jamunkar, Neha Madarkar, Darshana Nandekar, Ruchieta Kishty, Govindan Vijayaraghavan, Kavitha VC, Debabrata Roy, Partha Bhattacharjee, Anjuli Barai, Rajashekhar Durgaprasad, Latheef Kasala, Vanaja Vanajakshamma, A.G. Ravi Shankar, Rahul ER, Kanuri Prashanth, Prasad Shiva, Dilip Teja Naidu, Sunil Kumar, Dilipa Naik, Manasa Rao, Dinesh Jain, Sukhjeet Kaur, Anju Jain, Aarushi Jain, Kartikeya Bhargava, Dhriti Adak, Krishan Sharma, Kuldeep Chauhan, Vinay Kumar, Devina Igoor, Manjappa M, Vinushree K, Rathna RL, Haseena Begum, Vaibhavi PS, Bharath Kumar, Udigala Madappa Nagamalesh, Dayakar P, Sanjana Xavier, Swathi Balaraju, Vijay Kumar, Beena Lokesh, Rajeeve Kumar Rajput, Swati Sharma, Huma Yusuf, Arti Malik, Swati Singhal.

**Japan**

Yukihiro Koretsune, Seishu Kanamori, Kenichi Yamamoto, Koichiro Kumagai, Yosuke Katsuda, Keiki Yoshida, Kemji Sadamatsu, Fumitoshi Toyota, Yuji Mizuno, Ikuo Misumi, Hiroo Noguchi, Shinichi Ando, Tetsuro Suetsugu, Masahiro Minamoto, Hiroyuki Oda, Susumu Adachi, Kei Chiba, Hiroaki Norita, Makoto Tsuruta, Takeshi Koyanagi, Kunihiko Yamamoto, Hiroshi Ando, Takayuki Higashi, Megumi Okada, Shiro Azakami, Shinichiro Komaki, Kenshi Kumeda, Takashi Murayama, Jun Matsumura, Yurika Oba, Ryuji Sonoda, Kazuo Goto, Kotaro Minoda, Yoshikuni Haraguchi, Hisakazu Suefuji, Hiroo Miyagi, Hitoshi Kato, Tsugihiko Nakamura, Tadashi Nakamura, Hidekazu Nandate, Ryuji Zaitso, Yoshihisa Fujiura, Akira Yoshimura, Hiroyuki Numata, Jun Ogawa, Hiroshi Tatematsu, Yasuyuki Kamogawa, Kinshiro Murakami, Yutaka Wakasa, Masanori Yamasawa, Hiromitsu Maekawa, Sumihisa Abe, Hajime Kihara, Satoru Tsunoda, Katsumi Saito, Hiroki Tachibana, Ichiro Oba, Takashi Kuwahata, Satoshi Higa, Masamichi Gushiken, Takuma Eto, Hidetoshi Chibana, Kazuaki Fujisawa, Yuhei Shiga, Hirokuni Sumi, Toshihisa Nagatomo, Yoshihiko Atsuchi, Toshiro Nagoshi, Kazuhisa Sanno, Fumihiro Hoshino, Naoto Yokota, Masahiro Kameko, Toshifumi Tabuchi, Muneshumi Ishizawa, Yoshitake Fujiura, Daisuke Ikeda, Taku Seto, Tetsu Iwao, Norio Ishioka, Kohei Nii, Koichi Oshiro, Keizo Tsuchida, Yutaka Hatori, Motoshi Takeuchi, Hiroto Takezawa, Shinjiro Nagano, Masaaki Iwaki, Yuichiro Nakamura, Naomasa Miyamoto, Toshifumi Taguchi, Ko Ashida, Naoto Yoshizawa, Jun Agata, Seishiro Matsukawa, Osamu Arasaki, Tetsuji Shinjo, Shuji Fukuoka, Hirofumi Murakami, Kazuya Mishima, Mamoru Manita, Yoshiki Hata, Ichiro Sakuma, Kotaro Obunai, Ichiro Takamura, Mitsuyuki Akutsu, Toshihide Unoki, Yoshinori Go, Makoto Ikemura, Shoji Morii, Shigeru Marusaki, Hideo Doi, Mitsuru Tanaka, Takaaki Kusumoto, Shigeo Kakinoki, Chiga Ogurusu, Kazuya Murata, Masaki Shimoyama, Masami Nakatsuka, Yutaka Kitami, Yoichi Nakamura, Hiroshi Oda, Rikimaru Oyama, Masato Ageta, Teruaki Mita, Kazuhiko Nagao, Takafumi Mito, Tsutomu Saito, Junichi Minami, Mitsunori Abe, Masako Fujii, Makoto Okawa, Tsuneo Fujito, Toshiya Taniguchi, Tenei Ko, Hiroshi Kubo, Mizuho Imamaki, Masahiro Akiyama, Takashi Ueda, Hironori Odakura, Masahiko

Inagaki, Yoshiki Katsube, Atsuyuki Nakata, Shinobu Tomimoto, Mitsuhiro Shibuya, Masayuki Nakano, Kenichiro Ito, Masahiro Matsuta, Motoyuki Ishiguro, Taro Minagawa, Masamichi Wada, Hiroaki Mukawa, Masato Mizuguchi, Fumio Okuda Teruaki Kimura, Kuniaki Taga, Masaaki Techigawara, Morio Igarashi, Hiroshi Watanabe, Toshihiko Seo, Shinya Hiramitsu, Hiroaki Hosokawa, Mitsumoto Hoshiai, Michitaka Hibino, Koichi Miyagawa, Hideki Horie, Nobuyoshi Sugishita, Yukio Shiga, Akira Soma, Kazuo Neya, Tetsuro Yoshida, Kunio Akahane, Sen Adachi, Chiei Takanaka, Takashi Ueda, Saori Matsui, Hirofumi Kanda, Masanori Kaneko, Shiro Nagasaka, Atsushi Taguchi, Shuta Toru, Kazuyuki Saito, Akiko Miyashita, Hiroki Sasaguri, Jin Nariyama, Hiroyuki Miyamoto, Yusuke Nishida, Tatsuya Suga, Hiroki Nagata, Taketo Hatsuno, Takash Iwase, Kazuki Sato, Kazuya Kawai, Tomobumi Kotani, Tsuyoshi Tsuji, Hirosumi Sakai, Kiyoshi Nishino, Kenichi Ikeda, Kazuo Maeda, Tomohiro Shinozuka, Takeshi Inoue, Koichi Kawakami, Hiromichi Kitazumi, Tsutomu Takagi, Mamoru Hamaoka, Jisho Kojima, Akitoshi Sasaki, Yoshihiro Tsuchiya, Tetsuo Betsuyaku, Koji Higuchi, Masaaki Honda, Koichi Hasegawa, Takao Baba, Kazuaki Mineoi, Toshihiko Koeda, Kunihiro Hirasawa, Toshihide Kumazaki, Akira Nakagomi, Eiji Otaki, Takashi Shindo, Hiroyoshi Hirayama, Chikako Sugimoto, Takashi Yamagishi, Ichiro Mizuguchi, Kazunori Sezaki, Isamu Niwa, Ken Takenaka, Osamu Iiji, Koichi Taya, Hitoshi Kitazawa, Osamu Ueda, Hirokazu Kakuda, Takuya Ono, Seizo Oriso, Junya Kamata, Toshihiko Nanke, Itaru Maeda, Takashi Kawamoto, Yoshifusa Matsuura, Hiroki Teragawa, Yuichi Fujii, Shuichi Nomura, Tomohiro Ueda, Yasuyuki Maruyama, Kazuo Takei, Hajime Horie, Tetsutaro Kito, Hiroshi Asano, Koji Matsushita, Masaichi Nakamura, Takashi Washizuka, Tomoki Yoshida, Masato Sawano, Koji Matsushita, Shinichi Arima, Hidekazu Arai, Hisanori Shinohara, Hiroyuki Takai, Nobufusa Furukawa, Akira Ota, Kentaro Yamamoto, Kenji Aoki, Masahiko Abe, Rikiya Shinohe, Taku Yamamoto, Takeaki Kasai, Shunji Suzuki, Shu Suzuki, Kikuyo Takahashi, Nitara Shibata, Masayuki Watanabe, Yosuke Nishihata, Yutaro Nishi, Hiroyuki Niinuma, Yasuhiro Yokoyama, Hirotugu Mitsuhashi, Ryo Nakazato, Takeaki Shirai, Yumi Shiina, Atsushi Mizuno, Toru Adachi, Taku Asano, Ikki Komatsu, Masahiro Yamazoe, Toru Arino, Masaki Okuyama, Tetsushi Wakiyama, Tomoko Kato, Yasuo Sasagawa, Takeshi Tana, Ayano Ishihara, Yoshihito Hayashi, Shinichi Hirota, Yukihiko Abe, Yoshihiro Saito, Hirohide Uchiyama, Hiroshi Takeda, Hiroshi Ono, Shuichi Tohyo, Naoto Hanazono, Seiichi Miyajima, Hisashi Shimono, Takuma Aoyama, Shusaku Miyata, Shigekiyo Takahashi, Takahisa Ido, Makoto Yamaura, Keita Suzuki, Yuto Kumai, Gen Tanabe, Takehiro Yamada, Yuka Kawada, Yasunobu Shozawa, Yawara Niijima, Osamu Murai, Osamu Murai, Hideko Inaba, Katsumasa Nomura, Masatsugu Nozoe, Kazuo Suzuki, Toshiyuki Furukawa, Toshihiko Shiraiwa, Nobuhisa Ito, Shunichi Nagai, Kiyoharu Sato, Shiro Nakahara, Yujin Shimoyama, Naoko Ohara, Teruhiko Kozuka, Hideaki Okita, Masato Endo, Tsutomu Goto, Makoto Hirose, Emiko Nagata, Noriyuki Nakanishi, Toshizumi Mori, Shuichi Seki, Katsuhiko Okamoto, Osamu Moriai, Yoko Emura, Tsuyoshi Fukuda, Haruhiko Date, Shuichi Kawakami, Sho Nagai, Yuya Ueyama, Tetsuro Fudo, Mitsuru Imaizumi, Takuo Ogawa, Shunsuke Take, Hideo Ikeda, Hiroaki Nishioka, Norihiko Sakamoto, Nobuo Wakaki, Masatake Abe, Junji Doiuchi, Tetsuya Kira, Masato Tada, Ken Tsuzaki, Naoya Miura, Yasuaki Fujisawa, Wataru Furumoto, Susumu Suzuki, Akinori Fujisawa, Ryosai Nakamura, Hiroyasu Komatsu, Rei Fujiki, Shuichi Kawano, Keijiro Nishizawa, Yoji Kato, Junya Azuma, Kiyoshi Yasui, Toshio Amano, Yasuhiro Sekine, Tatsuo Honzawa, Yuichiro Koshibu, Yasuhide Sakamoto, Yukihiro Seta, Shingo Miyaguchi, Kojuro Morishita, Yasuko Samejima, Toyoshi Sasaki, Fumiko Iseki, Toshiyuki Kobayashi, Hiroshi Kano, Jaeyoung Kim, Hiroshi Yamaguchi, Yoichi Takagi, Yoko Onuki Pearce, Yasuyuki Suzuki, Takayuki Fukui, Toru Nakayama, Hideaki Kanai, Yoshiyuki Kawano, Tetsuji Ino, Hironori Miyoshi, Yasufumi Miyamoto, Masahito Shigekiyo, Shimato Ono, Yoshiyuki Kawano, Yutaka Okamoto, Satoshi Ubukata, Kojiro Koderu, Tatsuo Oriuchi, Naoki Matsumoto, Koichi Inagaki, Atsushi Iseki, Tomohiro Yoshida, Toshihiro Goda, Tsukasa

Katsuki, Atsushi Sato, Etsuo Mori, Toshio Tsubokura, Hiroshi Shudo, Shunichi Fujimoto, Tomohiro Katsuya, Yoshiyuki Furukawa, Hiroshi Hosokawa, Jun Narumi, Kiichiro Yamamoto, Masaki Owari, Takuya Inakura, Takafumi Anno, Kazuyuki Shirakawa.

### **Singapore**

Chi Keong Ching, Sandra Thng, Eric Lim, Yap Pei Wen, Toon Wei Lim, Ying Ming Lee, Winnie Sia, Vivian Fong, David Foo, Haiyan Li, Ong See Peng, Tristen Ng, Kelvin Wong, Siew Yoon Yap, Dan Dan Chen, Geraldine Lim, Colin Yeo, Tan Yuyang, Zhi Zi Tan, Wan Tin Lim, Fazlur Rehman Jaufeerally.

### **South Korea**

Seil Oh, JiHyun Sim, Hye Jin Song, Seungyun Lee, Tae-Eun Kim, HyunJu Yu, Hui Nam Park, Mi Suk Lee, Sung Yon Shim, So Hee Joo, Youngmi Park, Mihyang Park, Woo-Shik Kim, Eunjung Hwang, Eunsun Heo, Jin-bae Kim, Jung A Kim, HyeYoung Lee, Sun-joo Kim, Inae Han, Hiyan Ju Kim, Sung-Won Jang, Dong Bin Kim, SoYoung Yun, Dong Joon Kim, JinHee An, JiSuk Kwon, Dae Hyeok Kim and Kyung Mi Yoo, Jun Kim, Sang Eun Lee, Jeongsu Kim, DongRyeol Ryu, KyoungOk Her, Eun Hee Choi, Jaemin Shim, Sang Weon Park, Young Ran Jeon, JinYoung Ahn, Gyeong Hui Lee, Hye-Gyeong Jeon, Woo Jin Chi, Dae-Kyeong Kim, Seula Ye, Min Sun Ha, Sun Min Lee, Jin Hee Lee, Kyung Jin Lee, Yang-I Kim, Dong Ju Choi, Eun Hee Lee, Hee Kyung Choi, Woo Yeon Lee, EunJi Yoon, Yong Seog Oh, Yun Suk Son, Sae Rom Jeon, In-Ae Jung, Sukyung Park, Myeong-Chan Cho, Chung Suk Lee, Hack-Lyoung Kim, Sang Hyun Kim, Sang Hee Kim, EuMi Jang, Miseon Lim, Kyung Lee, Jiyeon Lee, Bo Ram Park, Hui-Kyung Jeon, Gyeong Hui Lee, Ki Tae Kim, Dong-Gu Shin, Seoyeon Jang, Jung-Min Kim, Kyung Hui Yim, Sang Weon Park, Jin Sik Park, Bomi Kami, Ju-Hee Ahn, Jae Seok Park, Jung Joo Ahn, Hoon Ki Park, Hee Suk Choi, Sang-Jin Han, Nari Ryu, NaYoung Kwon, Eun-Joo Choi, Jung Hoon Sung, JiSun Kang, So-Young Seo, HyeKyoung Wi, Hyung-Wook Park, JiHyeun Park, Mi Ra Kim, Jeong-Gwan Cho, JiSeon Kim, Haeim Kim, Gi-Byoung Nam, Sulhee Lee, Keun Hye Lee, Young Keun On, Sehyun Kim, SoYoung Jo, Seung Hyun Lee, Hoejeoung Park, Minsuk Rhue, Min Joo Seo, Hong Euy Lim, Sang-Min Lee, SeongWook Hwang, JaeJin Kwak, Hyeji Bae, HyeYoung Kye, JaeJin Kwak, Tae-Joon Cha, Eun A Choi, In Kyoung Noh, Taek Jong Hong, JaeHyun Park, JaeKyung Kim, Jeong Hee Moon, Ro Woon Lee, Kyeonghwa Hyun, Seong Hoon Park, Mi-Young Lee, Jung Han Yoon, Jung Ja Woo, Hye-suk Jang, Sunhui Han, AReum Park, Won Sook Son, Hae Jung An, Nam-Ho Kim, Hae Kyeong Jeong, Ae Lee Baek, Kee-Sik Kim, Sung-Guk Kim, Mal-soon Park, Mi Sun Kim, JuHee Kim, Byung Chun Jung, Jung Sook Kim, Gyo-Seung Hwang, Doo Lae Lee, Kye Ryun Lee, Ji Sun Kang, Joo Yeon Yoo, Young Mi Sohn, Chong-Jin Kim, Hye-Young Lee, Dae Hyeok Kim, Kyung Mi Yoo.

### **Thailand**

Sakda Rungaramsin, Riam Inphontan, Pimolwan Phunpinyosak, Peerapat Katekangplu, Piyanuch Sukklad, Porames Khunrong, Thanita Bunyapipat, Suree Yawila, Wanwarang Wongcharoen, Arintaya Phrommintikul, Siriluck Gunaparn, Pini Kaewsuwanna, Thida Chaipermkul, Khanchai Siriwattana, Theewarut Suttana, Ketsanee Khunkong, Waraporn Tiyanon, Thoranis Chantrarat, Panthipa Bamungpong, Supalerk Pattanaprichakul, Usa Kitmapawanont, Khanchit Likittanasombat, Bandit Naratreekoon, Kolltis Pongmorakot, Somluck Ninwaranon, Wacharin Suebjaksing, Doungrat Cholsaringkarl, Warangkana Boonyapisit, Napawan Pornnimitthum, Satchana Pumprueg, Sirichai Cheewatanakornkul, Ratchanee Sirichai, Arthiya Sriwichian, Treechada Wisaratapong, Songkwan Silaruks, Benjaporn Silaruks, Kittisak Sawanyawisuth, Pisit Hutayanon, Siripan Hongsuppinyo, Oranong Thangpet, Seksan Chawanadelert, Siriwan Ratchasikaew, Chuleerat Kongsin, Pairoj

Chattranukulchai, Rudeewan Khattaroek, Yongkasem Vorasettakarnkij, Boonsert Chatlaong, Yingsak Santanakorn, Khompiya Kanokphatcharakun, Piya Mongkolwongroj, Janwamol Phangyota, Atthakorn Wutthimanop, Thanawan Chaiyapong, Sasivimon Jai-Aue, Kanchana Sanit, Wattana Wongtheptien, Ongkarn Komson, Thanakorn Laksomya, Ampai Tangsirira, Suthasinee Poomiphol, Prathana Anekpunyakul.

### **Turkey**

Armagan Altun, Elif Yildirim, Hatice Aysu Ocal, Didar Aslan, Aycan Arslan, Ozge Ayar, Ali Aydinlar, Hulya Saribocek, Gizem Yavasla, Ozlem Aktas, Nilay Gungor, Ramazan Topsakal, Ibrahim Ozdogru, Leyla Kasa, Emine Yilmaz, Muruvvet Buyukpapuc, Mustafa Fehmi Bireciklioglu, Meryem Boyraz, Zeki Ongen, Fuat Polat, Elif Yilirim, Duygu Genc, Baris Ikitimur, Esra Kozig, Sinem Caliskan, Irem Ermec, Busra Gez, Fatih Koyuncuoglu, Gamze Avinc, Sadik Acikel, Ekrem Yeter, Ahmet Akyel, Mehmet Ali Felekoglu, Asel Canbolat, Deniz Alpay, Duygu Ozukaya, Yonca Kanal, Ayla Behnejad Kazancik, Faruk Yilmaz, Tilbe Kundak, Durmus Yildiray Sahin, Murat Cayli, Hasan Koca, Funda Balci, Hazal Sag, Taner Seker, Alaa Quisi, Berfu Dincyurek, Ilay Cevik, Yasemin Tuccar, Esra Sunduz Yigittekin, Ozcan Yilmaz, Dilek Zorlu, Elvan Ozcelik, Cansu Kiris, Mehmet Birhan Yilmaz, Funda Aras, Osman Beton, Hasan Pekdemir, Merve Zengin, Refah Karatas, Murdem Ketten, Mesut Demir, Vildan Yuksekdog, Aziz Celik, Hatice Rahim, Didem Uzun Alkan, Gulsum Daglik, Murat Sucu, Erdi Bilecen, Selin Budeyri, Sinan Bilecen, Levent Sahiner, Hikmet Yorgun, Duygu Ozukaya, Murat Ersanli, Deniz Koca, Ali Oto, Sercan Okutucu, Begum Yetis Sayin, Deniz Koca, Asel Conbolat, Deniz Alpay, Duygu Ozukaya, Mine Caglar, Sebnem Sebnem, Murat Ersanli, Sakine Sakiz, Esra Kozig, Sinem Caliskan, Irem Ermec, Busra Gez, Faith Koyuncuoglu, Gamze Avinc, Ertugrul Okuyan, Ekrem Bilal Karaayvaz, Rifat Yildirim, Sinan Varol, Fatih Kizkapan, Sakine Sakiz, Esra Kozig, Sinem Caliskan, Irem Emrec, Busra Gez, Faith Koyuncuoglu, Gamze Avinc, Dursun Aras, Didem Civit, Tuba Gulce Dodurga, Asel Canbolat, Deniz Alpay, Duygu Ozukaya, Yonca Kanal.

### **Argentina**

Florencia Rolandi, Natalia Vensentini, Vanesa Hansen, Adrian Cesar Ingaramo, Gustavo Alberto Ingaramo, Andres Javier Kleiban, Mariana Zillo, Maria Eugenia Yunis, Martin Racca, Carola Ricotti, Luciana Bergesio, Osvaldo Jose Angel Costamagna, Gustavo Alberto Sambadaro, Vanina Fernandez Caputi, Fernando Sokn, Jorge Tronge, Andrea Alvarez D'Amelio, Clara Buzzetti, Pablo Omar Schygiel, Hector Luciardi, Sofia Graciela Berman, Pablo Dragotto, Felicitas Fernandez Voena, Andres Javier Kleiban, Maria de los Milagros Mercedes Had, Karina Shatski, Nestor Centurion, Elena Emilia Piccirilli, Rodolfo Andres Ahuad Guerrero, Andrea Alvarez D'Amelio, Vanina Campisi, Mariano Fanuele, Agustina Ahuad Calvelo, Leonel Adalberto Di Paola, Flavio Javier Zurbrigk, Anabela Martinelli, Ricardo Dario Dran, Carlos Hector Gimenez, Javier Egido, Alicia Sossich, Fernando Colombo Berra, Cintia Schenkel, Melina Salinger, Luciana Montoya, Matias Jose Fosco, Enrique Pablo Gurfinkel, Branco Mautner, Simona Malengo, Emilio Daniel Alaguibe, Lucia Campo, Victor Alfredo Sinisi, Luis Rodolfo Cartasegna, Andrea Santoro, Maria Fernanda Alzogaray, Viviana Novas, Jessica Florencia Tinto, Oscar Gomez Vilamajo, Romina Cabrini, Javier Matkovich, Valentina Garate, Maria Eugenia Said Palladino, Jose Luis Ramos, Fabian Diez, Pablo Dragotto, Laura Susana Sanziani, Cintia Martinelli, Amaru Lopez, Sonia Sassone, Laura Maffei, Miguel Angel Vallejo, Marcelo Yantorno, Lucas Tonelli, Roxana Del Valle Martinez, Maria Goicoechea, Micaela Vallejo, Jessica Pontoriero, Rocio Munguia, Maria Levantini, Flavia Luciana Cilenti, Graciela Beatriz Perez Prados, Marina Ingratta, Gerardo Zapata, Anibal Agustin Damonte, Luciana Arias, Alejandro Meirino, Diego Conde, Jorge Atilio Belardi, Ignacio Nicolas De Urquiza, Alexandra Navarro, Juan Pablo Costabel, Guillermo Giacomi,

Maria Paula Giacomi, Ana Laura Tufare, Ramon Carrizo, María Florencia Edén, Alberto Alfredo Fernandez, Roberto Nicolás Potito, Silvina Borchowiec, Tatiana Bruno, Adrian Demetrio Hrabar, Jorgelina Casala, Claudia Funosas, Ana Lucia Cappi, Mario Alberto Berli, Paula Berli, Florencia Berli Milagros, Leandro Thomas, Mauricio Priotti, Germán Maehara, Fabian Ferroni, Celso Arabetti, Mariana Foa Torres, Maria Jose Izaguirre.

### **Brazil**

Dário Celestino Sobral Filho, Libania Ferreira, Tricia Souto Cysneiro, Eveline Lustosa, Jefferson Jaber, Luis Soares, Isabel Santos, Luciana Vidal Armaganijan, Dikran Armaganijan, Simone Barroso, Kleber Serafim, Maria Isabel Del Monaco, Costantino Roberto Frack Costantini, José Rocha Faria Neto, Carolina Stoll, Danilo Gonçalves Barroso, Costantino Costantini Ortiz, Daniele Komar, André Steffens, Camila Fonseca, Felipe da Silva Paulitsch, Weimar Kunz Sebba Barroso de Souzaem, Lohana Borges Queiroz, João David de Souza Neto, Dafne Lopes, José Márcio Ribeiro, Marcelo Silveira Teixeira Denise Guanaes, Paulo Ross, Verena Araujo, Luana Herek, Leonardo Pires, Oscar Pereira Dutra, Silvia Poletti, Rafael de March Ronsoni, Daniel Moreira, Vera Lucia Pereira, José Carlos Moura Jorge, Leonardo Spolaor, Cristaine Dias, Mariana Rodrigues Pius, Juliane Woehl, Adalberto Menezes Lorga Filho, Eduardo Palmegiani, Priscila Fabri, Paula Galeazzi, Thamyres Santini Arroio Cruz, Clotildes Queirantes, Luiz Bodanese, Tulio Ruaro Reichert, Fernanda Chieza, Rosa Vieira Homem, Ellen Hettwer Magedanz, Marcelo Westerlund Montera, Roberta Perreira, Carlos Henrique Del Carlo, Eliane Fernandes, Gabriela Melo, Esther Coste, Maria Fernanda Correia, Cristiano Pisani, Muhieddine Omar Chokr, Hurgo Bellotti Lopes, Ricardo Clemente Mingireanov, Talita Barbosa, Selma Cristina Quiaia Fortunato, Elaine Fernandes, Jamil Abdalla Saad, Thiago da Rocha Rodrigues, Barabara Silva, Crystielle Linhares, Maria Celia Marinho, Tânia Félix Lorenzato Fonseca, Eduardo Belisario Falchetto, Fernando Augusto Alves da Costa, Raquel Franchin Ferraz, Renato Lopes, Anelise Kawakami, Erika Watanabe, Mayara Vioto Valois, Gilson Roberto de Araújo, Lenisa Vila Boas, Euler Roberto Manenti, Máurer Pereira Martins, Adriana Silva, Priscila Aparecida Lodi, Aline Borba, Laisa Borrges Ferreira, Anderson Lacerda dos Reis, Nurma Ramos Pereira, Aline de Cassia Vieira dos Santos, Mariana Moraes Pontalti, Alexandre Guerreiro, Ana Paula Macagnan, Livia Pereira, Patricia Ely Pizzato, Milene Santos, Rafael Luiz Rech, Jose Francisco Kerr Saraiva, Larissa Trama, Carla Vicente, Camila Ormundo, Midia Costa, Tatiana Siqueira, Marina Caporale, Talita Silva, João Carlos Ferreira Braga, Lilian Stefanie da Silva, Daiane Santos, Alexandre Rodrigues, Fábio Villaça Guimarães Filho, Alexandre Negri, Paulo Gottardo, Carlos Moncada, Marcos Vinicius Seroqui, Dalton Precoma, Lucas Geralde, Cibelle Precoma, Thiago Felipe dos Santos, Cristina Paula Corrêa, Luiz Gustavo Vieira Torres, Fernando Roquette, Gilmar Reis, Ludmila Carvalho, Roberto Álvaro Ramos Filho, Caroline Nanzer Vital, José Da Silveira, Rodrigo Pavani, Estêvão Lanna Figueiredo, Bruna Edilena Paulino Azevedo, Beatriz Quirino, Gustavo Fonseca Werner, Roberto Vieira Botelho, Iara Resende, Cláudio Munhoz da Fontoura Tavares, Rogerio Tadeu Tumelero, Gilmar Junior, Norberto Toazza Duda, Leticia Mortari, Melissa Mazzoni, Helius Carlos Finimundi, Silvia Oss Emmer, Fábio Eduardo Camazzola, Edimar Daros, Juliana Anghinoni Andretta, Bruna Nadin, Cibelle Precoma, Sara Cardoso Boscato, Adriano Kochi, Diego Chemello, Juliani da dos Reis, Sabrina Guizzardi, Priscila Agliardi, Fernanda Igansi, César Cássio Broilo França, Jakeline Alves de Oliveira Gomes, Ana Paula Drummond Wainstein, Edmar Geraldo Ribeiro, Guido Bernardo Aranha Rosito, Heveline Roesch, Larissa Pacheco, Jordana Alba, Tatiana Vargas, Andressa Degen, Diego Alcoba, João Batista de Moura Xavier Moraes Junior, Fernanda Freire, Sheylla Ribeiro, Maria Aparecida Torres de Lacerda, Rogério Tadeu Tumelero, Gilmar Junior, Norberto Toazza Duda, Melissa Mazzoni, Claudio Munhoz da Fontoura Tavares, Leticia Mortari, Lilia Maia, Osvaldo Lourenço da Silva Júnior, Daniele Cristine Esteves, Osana Maria Coelho Costa Mouco, Maria Angelica Benez Teixeira

Lemos, Nadielly Codonho Góes, Marcelo Arruda Nakazone, Roberto Simões de Almeida, Lucas Frare, Bruna Unterkircher, Ney Carter do Carmo Borges, Fernanda Jannuzzi, Marco Antonio Dias, Luís Gustavo Gomes Ferreira, Etineia Gomes Lino, Arthur Freitas, Tatiane Viana, Manoel Lucas Correa e Silva, Angela Lopes.

### **Chile**

Ramón Corbalán, Ivonne Padilla, Jara Carmen, Benjamin Aleck Joseh Stockins Fernandez, Carola Lara, Humberto Montecinos, Yessica Campisto, Fernando Lanas, Ana Rebolledo, Elda Molina, Martín Larico Gómez, Carlos Astudillo, Margarita Vergara, Carlos Conejeros, Patricio Marin Cuevas, Alejandro Forero, Claudio Bugueño Gutiérrez, Patricia Cortes, Juan Aguilar, Sergio Potthoff Cardenas, Nelly Garcia Dominguez, German Eggers, Jessica Munoz Oyarzon, Cesar Houzvic, Veronica Olguin, Carlos Rey, Germán Arriagada, Claudio Villan Araneda, Gustavo Charme Vilches, Ximena Reyes Alvarez.

### **Mexico**

Carlos Jerjes Sanchez Diaz, Andres Gerardo Ortiz López, Hector David Rodriguez Flores, Claudia Atilano Arias, Jesus Jaime Illescas Diaz, Maria Ruiz Cornejo, Maricela Vidrio Velazquez, Maria Esther Garcia Muñoz, Marissa Gonzalez, Raul Leal Cantu, Pilar Ocampo, Conne Lizbeth Gonzalez Garcia, Conne Lizbeth Gonzalez Garcia, Maria Guadalupe Ramos Zavala, Sara Pascoe González, Ricardo Cabrera Jardines, Nilda Espinola Zavaleta, Victor Roa Castro, Salome Altamirano Bellorin, Enrique Lopez Rosas, Isis Lizeth Alarcon Zaragoza, Sukey Ochoa Aybar, Lucas Solis Morales, Guillermo Antonio Llamas Esperón, Irma Espinosa, Ana Ramirez Ibarra, Gabriela Romero Cardona, Edgar Eduardo Barcenás Rodriguez, Edgar Eduardo Barcenás Rodriguez, Hector Alejandro Martinez Resendiz, Maria Elena Felix Hernandez, Gerardo Pozas, Priscila Guajardo, Ernesto Cardona Muñoz, Sandra Hernandez Gonzalez, Norberto Matadamas Hernandez, Maria Candelaria Mancilla Ortiz, Adolfo Leyva Rendon, Adriana Ortiz, Norberto Garcia Hernandez, Rafael Trujillo Cortes, Manuel de los Rios Ibarra, Olivia Elena Espinoza Lopez, Luis Gerardo Gonzalez Salas, Nora Mendoza, Luis Ramon Virgen Carrillo, Oscar Garcia Garcia, Jose Vega Gonzalez, Humberto Jimenez, Aldo Guasco Herrera, David Lopez Villezca, Carlos Hernandez Herrera, Daniel Martinez Vasquez, Karla Yaneth Arizpe Aguilar, Aline Cecilia Meza Ramos, Juan Jose Lopez Prieto, Rodolfo Gaona Rodriguez, Patricia Padilla Macias, Efrain Villeda Espinosa, Angelica Villeda, Artuto Gil Sanchez Aguilar, Margarita Abreo, Miriam Chavarria, David Flores Martinez, Jose Velasco Barcena, Omar Fierro Fierro, Maria de la Merced Velazquez Quintana, Jorge Morales, Anais Rascon, Luz Eighty Garcia Prieto, Rosalva Avena, Lesly Facio, Ignacio Rodriguez Briones, Bernardo Vargas Berrueta, Monica Ramos Gonzalez, Irene Elizabeth Lira González, Jose Luis Leiva Pons, Jorge Carrillo Calvillo, Natalia Nikitina, Teresa Izquierdo, Humberto Alvarez Lopez, Gabriela Santana, Rafael Olvera Ruiz, Carlos Gerardo Cantu Brito, Fernando Flores Silva, Eduardo Julian Jose Roberto Chuquiure Valenzuela, Roxana Reyes Sanchez, Ricardo Alvarado Ruiz, Lidia Martínez Lares, Paulina Sida Perez, Alberto Esteban Bazzoni Ruiz, Erika Orpinel Almanza, Karla Daniela Monreal de Luna, Aglaé Romo Cerda, Juan Carlos Ubillo Davila, Sandra Roccio Fuentes Ortiz, Rocio Guadalupe Contreras Corona Alejandro Maximiliano Bancelos Lopez, Jose Luis Recio Gonzalez, Oscar Martin Lopez Ruiz, Fatima Perez, Luis Alberto Martinez Cruz, Julio Alberto Perez Sanchez, Nayeli Soto, Eduardo Montiel, Norma Juarez Garcia, Keren Sharon Perez Mendoza, Oscar Nandayapa Flores, Roberto Arriaga Nava, Patricia Padilla Macias, Jesus David Morales Cerda, Antonio Salinas, Sergio Piña Toledano, Euinice Aide Fernandez Zuñiga, Pedro Fajardo Campos, Daniela Cienfuegos, Karina Godoy, Silvia Verdugo Dojaquez, Elena Claudia Mora Respardo, Pablo Alfonso Madero Ayala, Maritza Arasely Uribe Rios, Guadalupe Susan Ramos Garcia, Pedro Fajardo Garcia, Adriana

Garcia Mejia, Patricia Ortiz, Glenda Hernandez, Irene Ortega, Mario Benavides Gonzalez, Jose Esparza Negrete, Carlos Rivera Ramos.

### **Austria**

Marianne Brodmann, Thomas Gary, Claudia Wöhrer, Claus Hagn, Johannes Foechterle, Johannes Foechterle, Heinz Drexel, Karl-Martin Ebner, Abdurahman Said, Daniela Zanolin, Claudia Stöcklöcker, Alexandra Schuler, Alexander Vonbank, Susanne Wäger, Peter Schwerzler, Helga Winkler, Kurt Huber, Claudia Wegmayr, Ioannis Tentzeris, Brigit Vogel, Johannes Riedl, Andrea Podczeck-Schweighofer, Fritz Freihoff, Thomas Priesnitz, Michael Winkler, Roland Breier, Bruno Schneeweiss, Bernadette Bruckner, Thomas Mark, Adrian Mirtl, Alfons Gegenhuber, Wilfried Lang, Agnes Lischka-Lindner, Sabine Eichinger-Hasenauer, Lisbeth Eischer, Peter Kaserer, Josef Sykora, Heribert Rasch, Bernhard Strohmmer, Uta Hoppe, Lynne Hinterbuchner, Erika Prinz.

### **Belgium**

Luc Capiiau, Hilde Capiiau, Farah Banaeian, Geert Vervoort, Ellen Deweerdt, Erwin Raymenants, Oscar Semeraro, Muriel Delvigne, Tom Vydt, Hans Rombouts, Chris Scheurwegs, Ellen Potoms, Inez Mestdag, Sofie Drieghe, Bart Wollaert, Benjamin Scott, Tim Weyn, Emile Keyzer, Marleen Bogaert, Martine Oreglia, Inge Joris, Dirk Denie, Christine Jacobs, Ingrid Develter, Frank Cools, Dieter De Cleen, Steven Hellemans, Johan Salembier, Jef Verheyen, Walter Smolders, Nancy Simons, Veerle Thyssen, Geert Hollanders, Jan Vercammen, Veerle Soufflet, Jan De Keyser, Dries De Cock, Melissa de Vos, Dirk Faes, Bert Vanhauwaert, Dirk Van Lier, Cathy Kuppens, Ann Vandorpe, Yohan Balthazar, Anne Christine Billiaux, Marc Delforge, Patrick Maréchal, Françoise Gits, Olivier Xhaet, Fabien Dormal, Harry Striekwold, Dirk Vandenbroeck, John Thoeng, Kurt Hermans, Hans Vandekerckhove, Chantal Smessaert, Hugues Verloove, Katarina Van Beeumen, Jan Nimmegeers, Christophe Borin, Frauke Gorre, An-Kristin Ascoop, Nancy de Weerd, Georges Mairesse, Monique Raepers, Wim Anné, Emma Vanhalst, Peter Pollet, Anne Dewispelaere, Florian Demuyne, Martin De Meyer, Tine Casier, Ivan Blankoff, Veronica Piamonte, Asuncion Conde Y Bolado, Michel Beutels, Peter Vandenbossche, Sophie Deckers, Lisa Helvasto, Stefan Verstraete, Karine Pieters, Flor Kerkhof, Ann Dhondt, Peter Vandergoten, Philippe Purnode, Joseph Richa, Severine Tahon, Pascal Godart, Anna-Maria Barbuto, Marianne Blockmans, Tim Boussy, David Derthoo, Christiaan De Niel, Van Hulle Tim, Hannelore Van Eeckhoutte, Nele Bouckaert, Marlies De Coninck, Philippe Desfontaines, Gabriella Tincani, Alex Heyse, Charlotte Vantomme, Becker Alzand, Frederik Van Durme, Isabelle Stockman, Marloes Everaert, Joeri Voet, Lies Vergauwen, Martine Lauwers, Yasmina Steyaert, Axel De Wolf, Chris Brike.

### **Czech Republic**

Jan Bultas, Hana Lubanda, Milan Zidek, Eva Zidkova, Alena Lorenzova, Petr Jansky, Petra Antonova, Jiri Zika, Jana Golova, Alexandra Lindourkova, Jaromir Chlumsky, Petr Potuznik, Renata Kratochvilova, Rudolf Spacek, Lucie Mahdalikova, Lucie Bockova, Adam Sulc, Lenka Dastychova, Vilma Machova, Ondrej Ludka, Alexandra Ludkova, Josef Olsr, Daniel Michalik, Lubos Kotik, Marketa Lajnerova, Blazej Racz, Michaela Horejsi, Lenka Janska, Tomas Drasnar, Richard Ferkl, Jan Hubac and Vera Hubacova, Ilja Kotik, Jaroslava Novakova, Petr Krca, Eva Krcova, Zdenek Monhart, Eva Prochazkova, Maria Majernikova, Hana Burianova, Pavel Hanzelka, Ondrej Jerabek, Martina Valtova, Iva Kopeckova, Jana Pisova, Lenka Chmelickova, Iveta Petrova, Lenka Palubova, Vratislav Dedek and Lucie Capova, Michaela Honkova, Jakub Honek, Petr Podrazil, Petr Reichert, Lenka Zizkova, Jindrich Spinar, Ruzena Labrova, Miroslav Novak, Jiri Vitovec, Veronika Vyhldalova, Jolana Lipoldova, Vaclav

Durdil, Alexandra Lindourkova, Lucie Riedlbauchova, Katarina Plocova, Martin Barsovsky, Jaroslav Sulitka, Jiri Lastuvka, Sarka Smetankova, Lenka Zizkova, Jakub Sveceny.

### **Denmark**

Jørn Nielsen, Steen Husted, Marianne Leth, Helena Dominguez, Henrik Nielsen, Ulrik Hintze, Anne-Mette Oksbjerg Svenningsen, Joan Hummelshøj, Lene Margrethe Tanggaard, Annette Nygaard, Søren Rasmussen, Arne Bremmelgaard, Christina Ellervik, John Markenvard, Kirsten Vesterager, Jan Børger, Jorgen Solgaard, Ebbe Eriksen, Peter Simonsen, Jakob Tilma, Thomas Løkkegaard, Michael Bruun, Jacob Mertz, Morten Schou, Krud Skagen, Helena Dominguez, Annie Therkelsen, Helena Dominguez, Jesper Hansen, Anita Meier, Ilan Raymond, Dorte Raae, Michael Olsen, Magnus Jensen, Natasaha Roseva-Nielsen, Lise Jensen, Therese Bang-Hansen.

### **Finland**

Pekka Raatikainen, Kati Helleharju, Hannaleena Nappila, Virpi Palomak, Olli Arola, Juhani Koistinen, Tuija Vasankari, Carmela Viitanen.

### **France**

Franck Paganelli, Didier Sanchez, Pauline Armangau, Deborah Setbon, Audrey Morioni, Floriane Robin, Joël Ohayon, Frédéric Casassus, Stéphane Lafitte, Eléonore Casassus, Elodie Ducasse, Jean-Yves Le Heuzey, Michel Galinier, Nathalie Rosolin, Yannick Gottwalles, Franck Paganelli, Didier Sanchez, Audrey Morioni, Floriane Robin, Deborah Setbon, Pauline Armangau, Philippe Loiselet, Jean-Joseph Muller, Mohamed Bassel Koujan, André Marquand, Sylvain Destrac, Olivier Piot, Nicolas Delarche, Josette Couleru, Xavier Giry, Christine Murguet-Badia, Anne Colomes, Jean-Pierre Cebron, Nathalie Decarsin, Maxime Guenoun, Dominique Guedj-Meynier, Lokesh A G, Daniel Galley, Christine Beltra, Mathieu Zuber, Anne Bonnetain, Pierre Amarenco, Agnes Kemmel, Emmanuel Ellie, James Kadouch, Pierre-Yves Fournie, Jean-Pierre Huberman, Nestor Lemaire, Gilles Rodier, Xavier Vandamme, Igor Sibon, Sylvain Ledure, Sabrina Debruxelles, Camille Girollet, Stephane Olindo, Mathilde Poli, Pauline Renou, Sharmila Sagnier, Nathalie Heyvang, Ledure Sylvain, Jean-Philippe Neau, Marie Hélène Mahagne, Alain Suissa, Antoine Mielot, Marc Bonnefoy, Jean-Baptiste Churet, Vincent Navarre, Frederic Sellem, Gilles Monniot, Jean-Paul Boyes, Bernard Doucet, Michel Martelet, Désiré Obadia, Bernard Crousillat, Joseph Mouallem, Etienne Bearez, Corinne Lepot, Jean Philippe Brugnaux, Alain Fedorowsky, Pierre Nazeyrollas, Jean-Baptiste Berneau, Angeline Barreau, Aurélie Pons, Estelle Corrihons, Frédéric Chemin, Margaux Treuil-Peraldi, Elodie Ducasse, Nadege Ansoult, Caroline Moreau.

### **Germany**

Sebastien Schellong, Andreas Ulbrich, Thomas Wolf, Carsen Mueller, Johannes Ullrich, Roswitha Frommhold, Kerstin Spranger, Lutz Pomper, Birgit Voigts, Sylvia Weichelt, Juliane Gehre, Mario Hahn, Harald Darius, Friederike Girke, Katja Schirmer, Sandra Gaulke, Thomas Braun, Tanja Toennishoff, Roya Sartipi, Viola Jaerisch, Elke Luczak, Carsten Meincke, Stefan Sommer, Astrid Maselli, Georg Koeniger, Andreas Kopf, Uwe Gerbaulet, Bernd-Thomas Kellner, Thomas Schaefer, Gabriele Jass, Sabrina Diez, Jan Purr, Ute Weiser, Enno Eißfeller, Karla Kirchner-Volker, Heinz-Dieter Zauzig, Peter Riegel, Christoph Axthelm, Juergen Wurziger, Anja Quietzsch, Janet Geyer, Hartmut Hohensee, Cornelia Fritz, Adrienne Heuer, Benjamin Schaefer, Gerd-Ulrich Heinz, Afra Heinz, Holger Menke, Andreas Pustelnik, Sabine Pustelnik, Stefan Zutz, Andrea Talkenberger, Wolfgang Eder, Zuzana Babjakova, Guenter Rehling, Dirk Glatzel, Norbert Ludwig, Petra Sandow, Henning Wiswedel, Cosmas Wildenauer, Wolfgang Wildenauer, Svetlana Wildenauer, Steffen Schoen, Christoph Reichelt, Steffi Turbanisch, Romy Schoene, Stephanie Zincke, Marian Christoph, Toralf Schwarz, Heike



Riessbeck, Adyeri Babyesiza, Regina Voelkel-Babyesiza, Maximilian Kropp, Sylvia Simon, Hans-Hermann Zimny, Marianne Hintze, Hildegard Floegel, Friedhelm Kahl, Andreas Caspar, Sabine Omankowsky, Torsten Laessig, Hermann-Josef Hartmann, Diana Amrhein, Kartin Tauber, Ramona Heeg, Gunter Lehmann, Aileen Grytzmann, Hans-Walter Bindig, Katharina Bindig, Gunter Hergdt, Susanne Hergdt, Dietrich Reimer, Cornelia Reimer, Joachim Hauk, Christl Hubrich, Holger Michel, Werner Erdle, Wilfried Dorsch, Aneta Tetlak, Janna Dshabrailov, Karl-Albrecht Rapp, Reinhold Vormann, Daniela Nicolaus, Thomas Mueller, Peter Mayer, Uwe Horstmeier, Jan Zak, Volker Eissing, Gabriele Menken, Heinz Hey, Heinz Leuchtgens, Volker Lilienweiss, Heiner Mueller, Kruth Kolitsch, Anja Fleck, Katja Bergner, Christian Schubert, Herrmann Lauer, Thomas Buchner, Gunter Brauer, Diana Kroll, Susanne Kamin, Karsten Mueller, Gabriela Mueller, Sylvia Baumbach, Kerstin Schmidt, Muwafeg Abdel-Qader, Dagmar Mohrmann, Anke Krueger, Hans-Holger Ebert, Lisa Mann, Helen Mortan, Antje Richter, Gunter Stenzel, Romy Meinecke, Carsten Schwencke, Stefanie Boehme, Manfred Geiger, Detlef Mathey, Kerstin Flint, Sebastian Schellong, Thomas Wolf, Carsen Mueller, Lutz Pomper, Andreas Ulbrich, Juliane Gehre, Johannes Ullrich, Roswitha Frommhold, Kerstin Spranger, Birgit Voigts, Sylvia Weichelt, Mario Hahn; Universitaetsklinikum Ulm, Ulm, Germany: Peter Bernhardt, Dominik Buckert and Uta Dichristin, Laszlo Karolyi, Yvonne Nickstadt, Kartin Boehme, Christin Rade, Kerstin Bonin, Kerstin Mikes, Franziska Guenthe, Britta Sievers, Veselin Mitrovic, Wilhelm Haverkamp, Nesrin Nasser, Marika Saegebarth, Philipp Lacour, Paula Muenkler, Luis Weitbrecht, Katja Hubert, Jens-Uwe Roehnisch, Susanna Scharrer, Florian Busch, Katja Helgert, Vanessa Klein, Julainne Wettengel, Susanne Zeifele, Carola Ravenhorst, Maria Schuppe.

### **Hungary**

Andras Papp, Andras Vertes, Gabor Szantai, Andras Matoltsy, Tunde Kiss, Nikosz Kanakaridis, Zoltan Boda, Erno Kis, Jusztna Feil, Balazs Gaszner, Ferenc Juhasz, Zsuzsanna Hollo, Peter Jen, Gizella Juhasz, Zsolt Ples, Veronika Forgo, Szilvia Gergely, Petra Gombos, Sandor Kancz, Eszter Fulop, Zoltan Laszlo, Boglarka Vandrus, Zoltan Radics, Zsolt May, Fruzsina Sztanyik, Bela Merkely, Anna Hermecz, Marianna Szabo, Nora Sydo, Ebrahim Noori, Maria Hollósiné Kovács, Tamas Habon, Kalman Toth, Szilvia Kovacsne Levang, Peter Polgar, Attila Szilagyi, Gabriella Szalai, Sandor Vangel, Andras Nagy, Gabriella Engelthaler, Istvan Szombati, Gabor Bogy, Eszter Kiralyhazine Gyorke, Judit Ferenczi, David Gulyas, Emese Dohovits, Anette Toth, Reka Szalo, David Cseresznyek.

### **Italy**

Giuliana Martini, Leone Maria Cristina, Attilia Pizzini, Eros Tiraferri, Rita Santoro, Sophie Testa, Cinzia Zecca, Giovanni Di Minno, Pasquale Ambrosino, Marco Moia, Simon Brahm, Teresa Maria Caimi, Roberta Frittella, Daniela Piazzolla, Roberta Frittella, Elena Mollica Poeta, Stefania Brusorio, Maria Tessitori, Giancarlo Agnelli, Federica Macellari, Erika D'Agostini, Marta Fedele, Roberto Cappelli, Michele Voglino, Daniela Poli, Roberto Quintavalla, Piera Maria Ferrini, Franco Cosmi, Raffaele Fanelli, Raimondo Massaro, Carmela DArienzo, Vincenzo Oriana, Gaterina Latella, Gianluca Sottilota, Raffaele Reggio, Roberto Santi, Leonardo Pancaldi, Giulio Boggian, Raimondo De Cristofaro, Leonardo Di Gennaro, Giuliana Guazzaloca, Gualtiero Palareti, Luisa Salomone, Angelo De Blasio, Carlo Ciabatta, Jorge Salerno Uriate, Vincenzo Guerrieri, Benedetta Montanari, Alfredo Bianchi, Riccardo Gorla, Flavia Lillo, Franca Minetti, Cinzia Scarone, Enrico Maria Pogliani, Monica Carpenedo, Grzegorz Bilo, Dr. Luca Grappiolo, Michele Accogli, Simona Longo, Antonio Mariani, Nino Ciampani and Francesca Calcagnoli, Anna Patrignani, Mauro Feola, Arturo Raisaro, Katharina Granzow, Luciano Fattore, Cosimo Nave, Andrea Mauric, Fabrizio Germini, Giuliana Duranti,

Gregorio Baglioni, Valerio Pannacci, Fulvio Forcignanò, Angelo Giombolini, Luca Tedeschi, Maria Settimi, Mario Berardi, Sergio Nicoli, Paolo Ricciarini, Roberto Nasorri, Antonio Argena, Pierdomenico Bossolasco, Bartolomeo Allasia, Paolo Ronchini, Claudio Bulla, Luciano Foppa, Alessandro Filippi, Maria Lusía Bottarelli, Antonino Tomasello, Filippo Tradati, Massimo Volpe, Maria D'Avino, Domenico Caruso, Maria Grazia Bongiorno, Luca Segreti, Silva Severi, Marco Breschi, Alessandro Capucci, Federico Guerra, Kate Pozniak Graziela Rangel, Marta Marcinekova, Corrado Lodigiani, Elena Banfi, Veronica Pacetti, Enrico Salomone, Gaetano Serviddio, Rosanna Villani, Aurelio Lo Buglio, Claudio Tondo, Viviana Biagioli, Eleonora Russo, Giuseppe Ambrosio, Giuseppe Ciliberti, Ezio Mesoletta, Paolo Golino, Giovanni Cimmino, Carmine Mazzone, Andrea Di Lenarda, Saverio Iacopino, Giuseppe Campagna Pierpaolo Occhilupo, Roberta Spirito.

### **The Netherlands**

Hugo ten Cate, Marieke Pavlicic, Noordwest Ziekenhuisgroep, Alkmaar, J.H. Ruiters, Andreas Lucassen, H.C. Klomps, Henk Adriaansen, Mirjam Debordes, Jan Jaap van Putten, Maarten Bongaerts, Laurens Westerman, Jannie Boon, Tineke Kloosterman, Mathijs Pieterse, Misannia Boersma-Slootweg, Salcudean Tania, Stan Vergos, Kris Gorrebeek, Coen van Guldener, Johannes Herrman, Femmy Bosman, Sara Dols, Laura Breukel, Jennifer Knaake, Sander Niehe, Elise Van Dongen Sandra Bruin, A.J.K. Roelse, S.H.K. Josien Krikken, Eileen Van Warners, Floor Geerlings, P.R. Nierop, Ingrid Danse, Nel Slingerland, Jurgen Akkerhuis, Sweder Van de poll, Marja van der Knaap, Irene Kort, Margaret Dirks, Pieter Hoogslag, J.H. Geertman, Agaath Stallinga-de Vos, Walter Hermans, Paul Melman, Tim van der Kley, Guido van Leeuwen, A. Pronk, Riny van de Loo, Jeanne de Graauw, B.E. Groenemeijer, Anastazia Jerzewski, E. M. Koomen, Suzanne Jansen, Rina Mulder, W. Terpstra, J.M.C. Van Hal, Anneke Grunewald, Cees Buiks, Paul Buiks, L.V.A. Boersma, Pim Tonino, Jur ten Berg Josine te Kaat, Wesley Jetten, Malu Kelderman, Judith De Graaf, Mike Bosschaert, Boudewijn Uppelschoten, Irene Vogel, Donia Mohamed, Madeleine van der Perk.

### **Norway**

Ingrid Dominguez, Dan Atar, Bjørn Løvås, Trude Berge, Eivind Berge, Hege Claussen, Per Anton Sirnes, Vivi Nilsen, Erik Gjertsen, Torstein Hole, Rigmor Bøen, Silje Rasmussen, Knut Erga, Arne Hallaråker, Marie O'Donovan, Gunnar Skjelvan, Sissel Strand, Anders Østrem, Beraki Ghezai, Arne Svilaas, Kristin Ringdalen, Peter Christersson, Torbjørn Øien, Aase Jekthammer, Svein Høegh Henrichsen, Anne Berit Lensebraaten, Jan Erik Otterstad, Karin Ausen, Jan Berg-Johansen, Hege Antonsen.

### **Poland**

Janina Stepinska, Elzbieta Kremis, Anna Konopka, Andrzej Gieroba, Malgorzata Biedrzycka, Lukasz Biedrzycki, Michal Ogorek, Aleksandra Szczepanska, Beata Wozakowska-Kaplon, Radoslaw Bartkowiak, Kamila Wesolowska, Rafal Bzymek, Elzbieta Jaskulska-Niedziela, Krystyna Loboż-Grudzien, Edyta Szuchnik, Magdalena Dziuba, Barbara Rzyckowska, Maria Loboż-Rudnicka, Jaroslaw Kosior, Ewa Pawlik-Rak, Wieslaw Supinski, Anna Szulowska, Jerzy Bartnik, Jerzy Kuzniar, Elzbieta Korczowska, Janusz Romanek, Roman Zaluska, Janusz Jankielewicz, Dariusz Andrzejewski, Dorota Kruczyk, Przemyslaw Chojnowski, Wojciech Rogowski, Adam Komlo, Jaroslaw Hiczkiewicz, Wojciech Faron, Lucyna Swiatkowska-Byczynska, Wojciech Wieczorek, Lech Kucharski, Joanna Araminowicz, Diana Kociolek, Agnieszka Orda, Adriana Jaremczuk-Kaczmarczyk, Marcin Gruchala, Bartosz Curyllo, Anna Frankiewicz, Piotr Minc, Justyna Rychta, Jolanta Niedek, Halina Krystyna Kowalczyk, Karol Cieslak, Maciej Olszewski, Pawel Szalecki, Grzegorz Kania, Pawel Wojewoda, Agnieszka Sidor, Malgorzata Krzciuk, Piotr Walasik, Anna Szpotowicz, Anna Barszcz, Malgorzata

Ozgowicz, Zbigniew Lajkowski, Bozenna Ostrowska-Pomian, Agata Krzesiak-Lodyga, Ewelina Kowal, Anna Jackun-Podlesna, Katarzyna Kalin, Jerzy Lewczuk, Marzena Stopyra-Poczatek, Agata Kaczmarzyk-Radka, Magdalena Wilgat-Szecowka, Renata Romaszekiewicz, Daniel Blaszczyk, Elzbieta Zinka, Agata Pawelska-Buczen, Karolina Zakutynska-Kowalczyk, Anita Biernacka, Agnieszka Karczmarczyk, Robert Kaliszczak, Malgorzata Chmielnicka-Pruszczynska, Dorota Lesniewska-Krynska, Iwona Wozniak-Skowerska, Maria Trusz-Gluza, Seweryn Nowak, Grzegorz Opolski, Agnieszka Kolodzinska, Marek Kiliszek, Marek Bronisz, Jacek Szafranski, Artur Jarzebowski, Malgorzata Brzustowska, Marcin Mielcarek, Marcin Ogorek, Nikolina Roszczyk, Dorota Rozewska-Furmanek, Pawel Ptaszynski, Grazyna Glanowska, Przemyslaw Wilczewski, Piotr Ruszkowski, Jerzy Leszczynski, Monika Smichura, Mateusz Splawski, Grzegorz Skonieczny, Krystyna Jaworska, Lukasz Bernat, Anna Raczynska, Malgorzata Troszczynska, Agnieszka Metzger-Gumiela, Maria Jaworska-Drozdowska, Tomasz Traczyk, Grzegorz Trzcinski, Ryszarda Piotrowicz, Ryszard Sciborski, Ewa Bekieszczyk, Beata Dolecka, Joanna Starak-Marciniak, Boguslaw Okopien, Malgorzata Klata, Iwona Kobielusz-Gembala, Marcin Basiak, Witold Szkrobka, Tomasz Dybala, Piotr Kukla, Wojciech Kurdzielewicz, Elzbieta Broton, Maciej Kluczewski, Marcin Czamara, Krzysztof Galbas, Agata Markiewicz, Krzysztof Cymerman, Alina Cieszynska, Jaroslaw Jurowiecki, Monika Machnikowska, Jolanta Neubauer-Geryk, Sebastian Tybura, Monika Figura-Chmielewska, Pawel Miekus, Waldemar Myszkowski, Agata Nowak, Aleksandra Wierzbicka, Karolina Majewska, Stanislaw Mazur, Ewa Miedlar, Monika Ambicka, Karolina Bugajska, Anna Starok, Artur Chmielowski, Michal Mazur, Roman Lysek, Grazyna Jaguszewska, Aleksandra Lysek-Jozefowicz, Grazyna Szumczyk-Muszytowska, Lukasz Wojnowski, Jacek Baszak, Bogdan Walko, Malgorzata Jargiello-Baszak, Wojciech Brzozowski, Teresa Rusicka-Piekarz, Andrzej Galaj, Malgorzata Zyczynska-Szmon, Waldemar Gadzinski, Joanna Luka, Rafal Cichomski, Marian Krzyzanowski, Grzegorz Raczak, Ewa Staniszevska, Pawel Gutknecht, Agnieszka Niemirycz-Makurat, Michal Wrobel, Ewa Kochanska, Mateusz Sciborski, Sebastian Tybura, Ewa Lewicka, Ludmila Danilowicz-Szymanowicz, Malgorzata Szwoch, Monika Figura-Chmielewska, Jolanta Skalska, Barbara Opielowska-Nowak, Lukasz Drelich, Justyna Kabat, Beata Dudzik-Richter, Ewa Domanska, Malgorzata Guziejewicz, Dorota Kustrzycka-Kratochwil, Malgorzata Sukiennik-Kujawa, Jadwiga Nessler, Ewelina Lichota, Ewa Gasior, Marta Wegrzynowska, Pawel Rostoff, Rafal Mariankowski, Jozef Lesnik.

### **Russia**

Roman Libis, Irina Kulchenkova, Natalia Shkatova, Gadel Kamalov, Dmitry Belenky, Olga Volodicheva, Olga Kungurtseva, Liudmila Egorova, Alexander Khokhlov, Olga Sinitsina, Svetlana Speshilova, Svetlana Chugunnaya, Elena Lileeva, Eduard Yakupov, Dmitry Zateyshchikov, Irina Zotova, Olga Barbarash, Evgeniya Zhuravleva, Elena Gorbunova, Tatyana Gorshkova, Yulia Belenkova, Tatiana Kupriyanova, Olga Miller, Olga Kungurtseva, Marina Blinkova, Evgeniy Mazur, Dmitry Platonov, Yuriy Orlov, Konstantin Zrazhevskiy, Tatyana Novikova, Fatima Bitakova, Yulia Moiseeva, Elena Polkanova, Konstantin Sobolev, Svetlana Erofeeva, Maria Rossovskaya, Yulia Shapovalova, Ashot Agakhanyan, Alla Kolesnikova, Konstantin Nikolaev, Alla Ovsyannikova, Oksana Zemlianskaia, Elizaveta Panchenko, Ekaterina Kropacheva, Anna Zateyshchikova, Ekaterina Volchkova, Victor Kostenko, Sergey Popov, Roman Batalov, Maria Poltavskaya, Anait Dumikyan, Olga Machilskaya, Anton Edin, Tamara Kolesova, Elena Aleksandrova, Olga Kropova, Oksana Drapkina, Vladimir Ivashkin, Olga Korneeva, Alexander Vishnevsky, Pavel Karchicyan, Oleg Nagibovich, Galina Nagibovich, Galina Monako, Elena Kuznetsova, Petr Chizhov, Elena Novikova, Tatyana Medvedeva, Yulia Ivanova, Marina Gurmach, Svetlana Rachkova, Olga

Lebedeva, Elena Shutemova, Svetlana Romanchuk, Margarita Ovchinnikova, Mikhail Sergeev, Daria Konyushenko, Polina Kuchuk, Borys Kurylo, Alexey Ushakov.

### Spain

Xavier Vinolas, Enrique Rodriguez F, Jose Mara Guerra, Concepcion Alonso, Marcos Rodriguez Garcia, Douglas Alvarez, Anna Espallargas, Enrique Pena Garcia, Francisco Mendez Zurita, Pere Alvarez Garcia, Nieves Palomo Merchan, Vianeth Rios, Maria Fernanda Lopez Fernandez, Beatriz Herrero Maeso, Maria del Carmen Gomez Castillo, Marta Fernandez, Diego Otero Tomera, Javier Batlle Fonrodona, Joana Costa Pinto Prego de Faria, Teresa Martinez, Luis Tercedor Sanchez, Alejandro Molina Leyva, Rosa Macias, Manuel Molina, Miriam Jimenez, Francisco Jose Bermudez Jimenez, Daniel Castro Fernandez, Maria Jose Jimenez Fernandez, Mercedes Cabrera Ramos, Miguel Alvarez, Maria Molina Jiménez, Carolina Torres, Salvador Tranche Iparraguirre, Norberto Sierra, Joaquin Aracil Villar, Pere Toran Monserrat, Antonio Negrete Palma, Stela Sanchez Parra, Josep Sorribes Lopez, Emilio Marquez Contreras, Jordi Isart Rafecas, Stela Sanchez Parra, Juan Motero Carrasco, Pablo Garcia Pavia, Mateo Cordoba, Ana Briceno Hinojo, Maria del Carmen Gutierrez del Val, Ariadna Gonzales Segovia, Casimiro Gomez Pajuelo, Manuela Pereda Armayor, Miguel Perez Carasa, Carmela Alonso, Luis Miguel Rincon Diaz, Miguel Castillo Orive, Paz Gonzalez, Irene Lasuncion, Luis Fernando Iglesias Alonso, Carolina Santolaya, Angel Grande Ruiz, Jordi Merce Klein, Miriam Garcia Bermudez, Veronica Quintern, Elisabet Serralvo, Jose Ramon Gonzalez Juanatey, Lilian Grigorian, Pilar Mazon, Venesa Garcia Millan, Ana Seoane Blanco, Maria Moure Gonzalez, Gonzalo Barón Esquivias, Marga Gavira Saenz, Mariela Campo Moreno, Ines Monte Collado, Herminia Palacin Piquero, Stela Sanchez Parra, Carles Brotons Cuixart, Esther Fernandez Escobar, Maria Rodriguez Morato, Carmen Rodrigo, Maribel Martines Mena, Ana Domenech Borrás, Maria Teixido Fontanillas, Miguel Casanova Gil, Maria Ubeda Pastor, Aileen Austria, Edelmira Barraquer Feu, Xavier Robiro Robiro, Stela Sanchez Parra, Joan Bayo i Llibre, Carme Roca Saumell, Maria Rosa Senan Sanz, Stela Sanchez Parra, Cecilia Corros Vicente, Norberto Sierra, Manuel Vida Gutierrez, Francisco Epelde Gonzalo, Roser Renom, Carlos Alexandre Almeida Fernandez, Sara Saez Jimenez, Encarnacion Martinez Navarro, Nuria del Val Plana, Gemma Tobajas, Marc Roca, Laia Riquelme Sola, Jordi Isart Rafecas, Enrique Escriba Montserrat, Stela Sanchez Parra, Inma Pareja Ibar, Juan Jose Montero Alia, Pilar Montero Alia, Ana Ferrer, Stela Sanchez Parra, Maria Barreda Gonzalez, Norberto Sierra, Maria Angels Moleiro Oliva, Manel Terns Riera, Roger Codinachs Alsina, Marta Dachs, Anna Bartes, Jose Iglesias Sanmartin, Norberto Sierra, Aida Iglesias Garcia, Mercedes Jimenez Gonzalez, Pilar Montero Alia, Stela Sanchez Parra, Juan Jose Montero Alia, Maria del Mar Rodriguez Alvarez, Eva Calvo Martinez, Anna Cortada Cabrera, Monserrat Olle Borque, Rolando Armitano Ochoa, Martin Cebollada del Misterio, Johan Cabeza Ramirez, Victoria Marina Ortega, Carmen Gines Garcia, Antonio Branjovich Tijuan, Eugeni Fernandez Mas, Stela Sanchez Parra, Benardi Jimeno Besa, Rosa Blanca Munoz Munoz, Juan Herreros Melenchon, Tomas Ripoll Vera, Joan Torres Marques, Javier Fosch, Salvador Marcus, Catalina Melia, Yolanda Gomez Perez, Manuel Jimenez Navarro, Miguel Lopez, Gloria Millan Vazquez, Natalia Andere, Lola Gomez, Hugo Nelson Orellana Figueroa, Victor Becerra Munoz, Alicia Guerrero Molina, Maria Vazquez Caamano, Marcelo Sanmartin Fernandez, Luisa Sanchez Mendez, Maria Fe Arcocha Torres, Izaskun Prieto, Aranza Manzanal Rey, Ane Elorriaga Madariaga, Gonzalo Marcos Gomez, Carolina Ortiz Cortes, Javier Mendoza Vazquez, Pablo Sanchez Calderon, Luis Enrique Lezcano Gort, Carmen Simon Valero, Gema Cancho Corchado, Maria Isabel Cotilla Marco, Andres Iniguez Romo, Maria Belen Lage Bouzamayor, Alicia Martin Vila, Marta Llobet Molina, Carlos Maria Diaz Lopez, Marisol Amaro, Saleta Barbeira, Pablo Juan Salvadores, Diana Montes, Seila Costas, Miguel Angel Prieto Diaz, Eduardo Hevia Rodriguez, Norberto Sierra.

**Sweden**

Mårten Rosenqvist, Jan Lindén, Kerstin Henriksson, Micael Elmersson, Arnor Egilsson, Karin Floren, Ulf Börjesson, Gunnar Svärd, Susanna Dzeletovic, Bo Liu, Anders Lindh, Rose-Mari Kangert, Lars-Bertil Olsson, Catarina Grässjö, Mikael Gustavsson, Lars Andersson, Lars Benson, Karina Rosenberg, Ann Mannermyr, Claes Bothin, Ali Hajimirsadeghi, Mina Shayesteh, Ruth Lissledal, Jessica Nyström, Björn Martinsson, Birgitta Jansson, Marianne Ericsson, Åke Ohlsson, Lisa Bastani, Kristina Skoglund, Faris Al-Khalili, Pia Löf, Håkan Lindvall, Ann-Britt Ekstrand, Peter Svensson, Camilla Nilsson, Katarina Thörne, Hans Händel, Pyotr Platonov, Anna Osberg, Fredrik Bernstenand, Orjan Stromqvist, Björn Eriksson, Agneta Lindberg, Annica Olofsson, Ingar Timberg, Mari Stjernberg, Milita Crisby, Helena Aaröe, Katarina Risbecker, Daniel Bengtsberg, Sirin Gudmundsson, Annelie Billger, Jan-Erik Karlsson, Dawid Kusiak, Grzegorz Bonkowski, Annika Koch, Jessika Samuelsson, Agneta Andersson, Marita Millborg, Ann-Marie Ohlin, Lennart Malmqvist, Gull-Britt Eriksson, Susanne Hahn, Johan Engdahl, Lisbeth Andersson, Jörgen Thulin, Carl-Johan Lindholm, Aida Hot-Bjelak, Eva Ahbeck, Marie Aman, Steen Jensen, Katarina Mansson, Carl Thorsen, Per Stalby, Johan Lugnegård, Hakan Ahlmark, Anna Pedersen, Annika Lettenström.

**Switzerland**

Jan Steffel, Ellen Saga, Stephan Winnik, Johann Debrunner, Daniela Amstutz, Alexander Westphalen, Juerg H. Beer, Alexandra Grau, Isberg Henriette, Christian Gustav Lutz, Kirsten Steden, Laura Boos, Philipp Baumgartner, Jana Efe, Marcel Frick, Emanuel Aegerter, Dipen Shah, Jasmine Bruegger, Alexandre Guinand, Guillermet Elise.

**Ukraine**

Iurii Rudyk, Valeriya Nemtsova, Olena Medentseva, Sergiy Pyvovar, Vira Tseluyko, Olga Romanenko, Oleksandr Karpenko, Liudmyla Todoruk, Svitlana Kizim, Svitlana Zhurba, Olga Proshak, Igor Kraiz, Ellina Kamenska, Oleksandr Parkhomenko, Oleksandr Shumakov, Iryna Kupnovytska, Irina Kutynska, Roxolana Belegai, Andriy Sapatyi, Nestor Seredyuk, and Roman Petrovskyy, Yuriy Mostovoy, Olha Mostova, Lesia Rasputina, Oleksiy Ushakov, Olena Koval, Pavlo Kaplan, Andrii Ivanov, Igor Kovalskiy, Dmitry Plevak, Yevgeniya Svyschenko, Larysa Bezrodna, Olena Matova, Tetiana Ovdiienko, Maryna Mospan, Oleg Sychov, Olena Romanova, Mykola Stanislavchuk, Galyna Berko, Liudmyla Burdeina, Oleg Kraydashenko, Vladislav Varenov, Roman Stets, Alina Khmelyova, Andriy Yagensky, Mykhailo Pavelko, Susanna Tykhonova, Olena Khyzhnyak, Ivan Fushthey, Valentyn Mochonyi, Olena Chabanna, Inna Daniuk, Olexandr Palamarchuk.

**United Kingdom**

Will Murdoch, Naresh Chauhan, Daryl Goodwin, Louise Lumley, Ramila Patel, Philip Saunders, Bennett Wong, Alex Cameron, Philip Saunders, Niranjana Patel, P Jhittay, Andrew Ross, M S Kainth, Karim Ladha, Kevin Douglas, Gill Pickavance, Joanna McDonnell, Laura Handscombe, Trevor Gooding, Helga Wagner, Cumberlidge, Colin Bradshaw, Catherine Bromham, Kevin Jones, Shoeb Suryani, Richard Coates, Bhupinder Sarai, W Willcock, S Sircar, John Cairns, A Gilliland, Roman Bilas, E Strieder, Peter Hutchinson, Anne Wakeman, Michael Stokes, Graham Kirby, Bhaskar Vishwanathan, Nigel Bird, Paul Evans, M Clark, John Bisatt, Jennifer Litchfield, E Fisher, Tim Fooks, Richard Kelsall, Neil Paul, Elizabeth Alborough, Michael Aziz, C Ramesh, Pete Wilson, Simon Franklin, Sue Fairhead, Julian Thompson, Hasan Chowan, Gary Taylor, John Wakeling, Dawn Tragen, Matt Parfitt, Claire Seamark, Carolyn Paul, Mark Richardson, Angus Jefferies, Helen Sharp, Hywel Jones, Claire Giles, Matthew Bramley, Philip Williams, Jehad Aldegather, Simon Wetherell, William Lumb, Phil Evans, Frances Scouller, Neil Macey, Stephen Rogers, Yvette Stipp, Richard West, Philip

Pinney, Paul Wadeson, John Matthews, Preeti Pandya, Andrew Gallagher, T Railton, Emyr Davies, Jonathan McClure, Marc Jacobs, Claire Hutton, R Thompson, Bijoy Sinha, Keith Butter, Susan Barrow, Helen Little, David Russell, Ulka Choudhary, Ikram Haq, Paul Ainsworth, Claire Jones, Phil Weeks, Jane Eden, Lisa Gibbons, Janet Glencross, Alison MacLeod, K Poland, Conor Mulolland, A Warke, Paul Conn, D Burns, R Smith, R Kamath, Jonathan Webster, Ian Hodgins, Stephen Vercoe, Paul Roome, Hilary Pinnock, Jayesh Patel, Amar Ali, Nigel Hart, Richard Davies, Nigel De-Sousa, Catherine Neden, Mark Danielsen, Purnima Sharma, Sophia Galloway, Charlotte Hawkins, Raife Oliver, Martin Aylward, Mira Pattni, Gordon Irvine, Shahid Ahmad, Catherine Rothwell, Fiaz Choudhary, Sabrina Khalaque, Stephanie Short, Sharon Peters, Warwick Coulson, Neil Roberts, Amy Butler, Steven Coates, Ben Ward, Daniel Jackson, Steve Walton, Diane Shepherd, Toh Wong, Mark Boon, Melanie Deacon, David Cornelius, Sarah Davies, Ben Frankel, Nick Hargreaves, Henry Choi, Jon Sumner, Tim Myhill, Salah Estifanos, Diane Geatch, Justin Wilkinson, Richard Veale, Karen Forshaw, Rob Hirst, Kashif Zaman, Catherine Liley, Rebecca Wastling Paul McEleny, Andre Beattie, Philip Cooke, Mike Wong, Mark Pugsley, Chaminda Dooldeniya Greg Rogers, James Bennett, Polly Jacobs, Rajesh Muvva, Matthew Adam, Robin Fox, Nicolas Thomas, Simon Cartwright, Rory Reed, Simon Randfield, Christine A'Court, Ann Flynn, Andrew Halpin, Shoeb Suryani Simon Dobson, Louise Lomax, Minnal Nadaph, Iain Munro, Jane Goram, Helen Stoddart, Phil Simmons, John Shewring, Emma Bowen-Simpkins, Mark Rickenbach, Polly Jacobs.

### **Australia**

Adam Blenkhorn, Harry Gibbs, Leverne Hesketh, Janice Boys, Charmaine Morahan, Tracey Mackney, Bhuwanendu Singh, Carol Singh, Monica Campo, Rosemary Beveridge, Laurie McKeon, Elizabeth Vardon, Penny Astridge, Lyne Parsons, Lesley Carlton, Geoffrey Oldfield, William van Gaal, It Meng Tsay, Vicki Lawlor, Chelsea Webster, Damien Cresp, Elizabeth Buckley, Rinku Rayoo, Mary Park, Uwais Mohamed, Naveen Sharma, Vivek Muhta, Elizabeth Vardon, Amie Cho, Walter Abhayaratna, Emily Wilford, Katherine Johnson, Kate Hayes, Natasha Thomas, Renee Eslick, Mehdi Eskandari, Philip Thomson, Vicki OMay, Nathan Dwyer, Catherine McIntosh, Lynette Reid, Teresa Grabek, Karen Patching, Andrew Black, Ben Costello, Rachel Lloyd, George Lukas, Joseph Amin, Ron Lehman, Cameron Singleton, Hazel Morrison, Tanya Patching, Mandy Lehman, Sam Lehman, Jens Kilian, Marika Seremetkoska, Jo-Dee Myers, Deirdre Upton, Alla Waldman, Changjie Song, Joanna Ramachenderan, David Coulshed, Michael Fitzpatrick, Michele MacKenzie, Lisa Barry, George Touma and Inaam Ullah, Andrei Catanchin, Michelle Bonner, Claire Batta, Mary Vorster, Vincent Paul, Nikola Stoyanov, Samantha Thompson, David Colquhoun, Aurelia Connelly, Lara Petelin, Dylan Barnes, Nigel Appleby, Tara Kinnane, Hilary Morrison, Antonio Ferreira-Jardim, Bojana Petrovic, Hosen Kiat, Lisa Wallis, Helena Setio, Anil Aggarwala, Kiran Swaraj, Imran Kassam, David Eccleston and Karen Patching, John French, Maria Plotz, Craig Juergens, Suzanne Raynes, Natalia Sequalino, Kelsey O'Brien, Sally-Anne Hoddy, Tuan Nguyen, Christian Mussap, Hany Dimitri, Krishna Kadappu, Dominic Leung, Alexandra Croucher, Bronte Ayres, Jessie Palmer, Jean Tarrant, Leon Zimmet, Tanya Patching, Marilyn Dolman, Peter Blombery, Helen Rashad, Claire McCarthy, Thanh Phan, Kitty Wong, Lauren Sanders, James Rogers, Bets Conway, Jonathan Sturm, Margaret Webb, Veronica Zenteno, David Crimmins, Anna Schutz, Susanne Rhodes, David O'Donnell, Karen Patching, Sang Cheol Bae, Harry Gibbs, Vathy Nagalingam, Patrick Carroll, Megan Ratcliffe, Maree Duroux, Samantha Shone, Johnathon Hunter, Mayank H Modi, Richard Geraghty, Greg Starmer, Shane Preston, Michelle Gosley, Sue Richmond, Sue Dixon, Steven Sutcliffe, Margaret Arstall, Katrina Macmillan, Purendra Pati, Jann Parkinson, Jane Rose, Maurits Binnekamp, Jennifer Brimley, Ellie Watson, Prakriti

Shrestha, Megan Higgs, Astin Lee, Stephen Mackay, Miyar Prathap Hegde, Taufik Fetahovic, Martin Walker, Joe Famia, Janene Gibbs.

### **Canada**

John Eikelboom, Sam Schulman, Marlene Robinson, Robert Luton, Shannen Douglass, Fraser Gibson, Krystine Cooper, Milan Gupta, Ana Maria Sindilar, Lidia Lepore, Lekraj Nimraj, Mitra Mohammadi, Ranjit Kahlon, Amritanshu Shekhar Pandey, Michelle Pandey, Linda Snell, Stephen Cheung, Jan Kornder, Lynn Breakwell, Tracy Cleveland, Jordana Largy, Alayna Ewert, Shannon Wong, Philippe Beaudry, Kathryn Beaudry Judy Dunnigan, Celine Bergeron, Gordhan Jethoo, Félix Ayala-Paredes, Caroline Lamoureux, Suzanne Maltais, Sonia Nadeau-Lapointe, Veronique Dagenais, Marie-Claude Grenier, Claude Jean, Joseph Berlingieri, Fern Petrie, Stephen Lewis, Chris MacRae, John Heath, Linette Scott, Jane Drown, Germain Poirier, Sandrine Spearson, Emilie Douville, Karine Primeau, Isabelle Neas, Julie Gaudreault, Miranda du Preez, Patricia Roberts, Patti Roberts, Anna Kubanska, Judy Vivic, Nathaly Reynoso, Bradley Schweitzer, Timothy Barkowski, Stephen Burns, Sally Watson, Patti Roberts, Reginald Nadeau, Georgeta Sas, Zahra Djaidani, Sadia Daheb, George Dresser, Donald Farquhar, Richard Kim, Rita Moor, Heather Vosper, Lara Whatmore, Natalie Crown, Ripple Dhillon, Julie Bigcanoe, Nanci Bignell, Tomasz Hruczkowski, Maria Raines, Andrea Lavoie, William Semchuk, Payam Dehghani, Laurie Ferleyko, Cheryl Altwasser, Sheila Kelly, Ratika Parkash, Debbie Wright, Lisa Carroll, Ann Fearon, James Cha, Rebecca Otis, Judy Otis, Elizabeth Burke, Benoit Coutu, Denise Fournier, Julie Fleury, Isabelle Denis, Paul MacDonald, Jeanie MacIsaac, Kathleen Hines, Annette Wood, Christine Hines, Joy Howard, Brian Ramjattan, Wayne Gulliver, Bonnie Clarke, Teri Trahey, Jorge Bonet, Dennis Rupka, Leanne Kwan, Katherine Haveman, Michael Kammermayer, Jacquie Stevenson, Saul Vizel, Beverley Fox, Paul Angaran, Kamran Ahmad, Victoria Korley, Arnold Pinter, Paul Dorian, Iqwal Mangat, Theresa Aves, Sameh Fikry, Wagdy Basily, Ana Maria Jackson.

### **Egypt**

Hany Ragy, Annie Ohanissian, Ahmed Mowafy, Azza Katta, Mazen Tawfik, Moustafa Nawar, Eman Zaatout, Mohamed Sobhy, Ahmed Soliman, Seif Kamal Abou Seif, Tarek Khairy, Ahmed Abd El-Aziz, Michael Sobhy, Nasser Taha, Ashraf Reda, Nevein Sami, Mohamed Reda, Atef Elbahry, Mohamed Setiha, Sameh Samir, Hanan Salem, Mohamed Gamal El Din, Magdi Elkhadem, Ali Mohsen, Adel El-Etreby, Shehab El Etriby, Adham Abdel Tawab.

### **South Africa**

David Kettles, Gerda Du Plessis, Debbie Browne, Penny Jackson, Junaid Bayat, Heidi Siebert, Craig Phillip Franklin, Petronella Nagel, Maria Booysen, Adrian Horak, Elwyn Lloyd, Lindy Henley, Ynez Kelfkens, Riaz Garda, Soraya Cassimjee, Loice Mavhusa, Barry Jacobson, Judy Sasto, Gladys Conway, Leonie Smith, Claire Cannon, Jeannie Marks, Thayabran Pillay, Margo Botha, Michele Guerra, Lelanie van Zyl, Anna-Marie Stapelberg, Deidre Oosthuizen, Louis van Zyl, Marshall Heradien, Judy Anne Finlaison, Tania Ellis, Francois van Zyl, Hendrik Theron, Lorinda de Meyer, Ellen Makotoko, Marinda Karsten, Andonia Page, Andrew Murray, Heather Christie, Cecilia Boshoff, Rikus Louw, Garath Tarr, Annalie Skein, Deon Greyling, Roelof Diederichs, Pindile Mntla, Lillian Rikhotso, Siddique Ismail, Anna Isaacs, Aziza Davids, Mariette Pelsler, Siphon Hlengwa, Fayzal Ahmed, Charmaine Chami, Johannes Engelbrecht, Marlene Mostert, Wilhelmina Pretorius, Andrew Ramdass, Muhammed Moosa, Indhranie Naidoo, Shambu Maharajh, Wessel Oosthuysen, Elizabeth Oosthuysen, Cornel Bester, Mohammed Moosa, Rehana Loghdey, Shireen Safodien, Mishka Salie, Farhaad Shaik, Rosemary Matthews, Veronica Ueckermann, Andre Ueckermann.

**United Arab Emirates**

Wael Al Mahmeed, Irfan Maqsood, Abdullah Al Naeemi, Maher Makdad, Ghazi Yousef, Ralph Manzano, Karen Magdaluyo, Steve Teves, Nooshin Bazargani, Azbin Abdul, Munther AlOmairi, Amna Al Mulla, Rajan Maruthanayagam, Abdul Rehman, Preetha Haridas, Rupesh Singh, Shereef El Bardisy, Sharmila Jadhav, Preetha Haridas, Ahmed Naguib, Mohamed Ibrahim, Rehab Mohamed, Amrisha Agrawal, Jameelah Dominguez, Mukesh Nathani, Ehab M. Esheiba, Nidhi Sharma, Mohammed Thanzeel, Rahul Sharma, Adel Wassef, Rajeev Gupta.

**United States**

Michael Cox, Erin Malone, Scott Beach, Melanie Eley, April Brown, Cheryl Verdi, Peter Duffy, Tim Richardson, Anne Dickerson, Valerie Palumbo, Shauna Eggertson, Pamela Mason, Stephen Falkowski, Elizabeth Burkett, Tammy Parrott, Karen Johnson, Kevin Ferrick, Ronald Zolty, Sandy Congal, Auris Browne, Miguel Franco, Celine Garcia, Paula Gentry, Melialoha Bartlett, W. Michael Kutayli, Andrew Merliss, Rose Saalfeld, Cheryl Orosco, Nicci Thompson, Annette Quick, Paramdeep Baweja, Daniel Pauly, M. Javed Ashraf, Mickie Keeling, Niraj Sharma, Jowanna Kerr, Marsha Headlee, Vance Wilson, Terry Purcell, Jennifer Langdon, Pamela Jones, Stephen Miller, Scott West, Heather Theobald, Kim Smith, Allison Jones, Lorlie Evans, Mark Alberts, Patricia Knowles, Jan Cameron-Watts, Edwin Blumberg, Susan Paserchia, Roddy Canosa, Elise Hartranft, Susan Felpel, Sarah Jasinski, Ted Gutowski, Susan Karl, Rodney Ison, Tammy Lincoln, Butcher Stephanie, Paula Shaw, Jorge Garcia, Edward Massin, Teresa Hicks, Paul Mullen, Sherry Raziano, Howard Noveck, Fatema Hakimi, Debra Merritt, Abbas Haideri, Pamela Rama, Jill DePauw, Doran Cassidy, Rajneesh Reddy, Melanie Bentley, Marcus Williams, Jin Ah Lee, Deborah Diercks, Daniel Nishijima, Laura Jones, Toni Harbour, Ben Mooso, Allyson Sage, Tirath Sanghera, Michaela Canova, Keith Ferdinand, Patrice Delafontaine, Gholam Ali, Nana Asafu-Adjaye, Suzanne Bowers, Ihsan Haque, Nicole Pickelsimer, Robert Mendelson, Tazrin Tripti, Janaya Raynor, Genna Pearl, Kelly Cervellione, Sridevi Pitta, Kent Davis, Benji Hawkins, Michael Lay, Debbie Fielder, Christopher Herrick, Jay Shoemaker, Daniel Theodoro, Kaharu Sumino, Gregory Ewald, Vanetta Worthy, Anne Thatcher, Lynn Henson, Kelly Ball, Catharine Richard, Jessica Peterson, Charles Treasure, Candy Robertson, Michelle Parker, Lisa Treasure, Joseph Minardo, Moustafa Moustafa, Samuel Emelife, Cas Cader, Sommer Morton, Walter Pharr, Katie Jenkins, Lauren Talton, Bryan Bray, Amy Riddle, Jill Woody, Alisha Oropallo, Farisha Baksh, Sally Kaplan, George Platt, Margaret Thorne, Jeremy Love, Kimberlee Harris, Jaspal Gujral, Peggy Best, Celestine Williams, James Welker, Kathleen Gray, Kristine Wood, Firas Koura, Lori Akers, Margie Duff-Coots.